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1A. SUMMARY 
Lentiviral vectors (LVs) are vectors of choice for many gene therapy applications 
since they mediate long term gene expression and can transduce dividing and non-
dividing cells. Recently, efficient targeting of LVs pseudotyped with the measles virus 
(MV) glycoproteins has been reported. However, MV antibodies in patients might limit 
the clinical use of these vectors. Thus, aim of this study was the development of 
targeted LVs pseudotyped with the glycoproteins of Tupaia paramyxovirus (TPMV). 
Since this animal paramyxovirus does not infect humans, no TPMV antibodies in 
patients are expected. For efficient incorporation in LVs, the TPMV glycoproteins, the 
hemagglutinin (H) and fusion (F) protein, were modified by truncation of their 
cytoplasmic tails. Targeting was achieved by displaying a single-chain antibody 
against the B cell surface marker CD20 on the H protein. The modified proteins were 
biochemically characterized and tested for their functionality. Unexpectedly, it was 
observed that an additional proteolytic cleavage of the F protein occurs during 
activation, resulting in the fragments F1a, F1b and F2. The newly identified fragment 
F1a was detected in virions and in supernatant of transfected cells. The F1a/F1b 
cleavage site was mapped and a cysteine protease was identified as likely activating 
protease. The data indicate that F protein processing is more complex than 
expected. 
After characterization, the modified TPMV glycoproteins were screened in all 
combinations for their ability to form functional pseudotyped LVs. Most efficient 
pseudotype formation was achieved with CT truncations of 80 amino acids (aa) for H 
(HΔ80αCD20) and 32 aa for F (FΔ32) (titers ~ 106 t.u./ml). The resulting vectors 
selectively transduced CD20-positive cells in a mixed cell population. Furthermore, 
they mediated efficient gene transfer into activated and quiescent primary human B 
cells. Neutralization assays showed that TPMV-pseudotyped vectors were not 
neutralized by human sera containing MV antibodies.  
In conclusion, it was demonstrated that targeted LVs pseudotyped with TPMV 
glycoproteins can be generated and escape neutralization by MV antibodies. 
Remarkably, the vectors are able to efficiently transduce even quiescent B cells. 
Hence, they might be a valuable vector choice when systemic application of targeted 
lentiviral vectors in humans is required. 
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1B. ZUSAMMENFASSUNG 
Lentivirale Vektoren (LV) sind für viele Anwendungen in der Gentherapie besonders 
gut geeignet, da das eingebrachte Gen über einen langen Zeitraum exprimiert wird 
und sie mitotisch aktive und inaktive Zellen transduzieren können. Kürzlich wurden 
zielgerichtete LV entwickelt, welche mit Masernvirus (MV)-Glykoproteinen 
pseudotypisiert sind. Allerdings würden MV-Antikörper in Patienten die klinische 
Anwendung dieser Vektoren wahrscheinlich erschweren. Deshalb wurden in dieser 
Arbeit LV entwickelt, welche mit den Glykoproteinen des Tupaia paramyxovirus 
(TPMV) pseudotypisiert sind. Da es sich dabei um ein für den Menschen nicht 
infektiöses Tier-Paramyxovirus handelt, werden keine Antikörper in Patienten gegen 
dieses Virus erwartet. Für einen effizienten Einbau der TPMV-Glykoproteine in LV, 
nämlich das Hämagglutintin (H) und Fusionsprotein (F), wurden die 
zytoplasmatischen Domänen (ZD) der Proteine verkürzt. Zielgerichteter Zelleintritt 
wurde ermöglicht, indem ein einkettiges Antikörper-Fragment (single chain antibody, 
scAb) gegen das B-Zell-Oberflächenmolekül CD20 an das H-Protein fusioniert 
wurde. Die modifizierten Proteine wurden biochemisch charakterisiert und auf ihre 
Funktionalität geprüft. Dabei wurde ein neues Fragment des F-Proteins detektiert 
(F1a), das aus einer unerwarteten zusätzlichen Spaltung des F-Proteins stammt und 
sowohl in Virionen als auch im Überstand transfizierter Zellen nachgewiesen wurde. 
Die entsprechende Spaltstelle wurde lokalisiert und eine Cystein-Protease als 
wahrscheinlich aktivierende Protease identifiziert. Die Daten deuten darauf hin, dass 
die Aktivierung des F-Proteins komplexer ist als ursprünglich gedacht.  
Die modifizierten Glykoproteine wurden des Weiteren in allen Kombinationen darauf 
getestet, funktionale pseudotypisierte LV zu bilden. Am effizientesten war eine 
Verkürzung der ZD von 80 Aminosäuren (AS) für H (HΔ80αCD20) und 32 AS für F 
(FΔ32) (Titer ~ 106 t.u./ml). Die entsprechenden Vektoren transduzierten selektiv 
CD20-positive Zellen in einer gemischten Zellpopulation und außerdem aktivierte und 
ruhende primäre humane B-Zellen. Neutralisations-Experimente zeigten, dass die 
Vektoren nicht von Humanserum mit MV-Antikörpern neutralisiert werden. 
Die in dieser Arbeit entwickelten Vektoren ermöglichen gezielten Zelleintritt und 
transduzieren bemerkenswerter Weise sogar ruhende B-Zellen. Folglich würden sie 
sich sehr für gentherapeutische Anwendungen in Menschen eignen. 
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2. ABBREVIATIONS 
 
α anti- 
αCD20-scAb single-chain antibody directed against CD20 
A absorption or amper 
Aa amino acids 
Ac acetate 
Amp ampicillin 
APS ammonium peroxydisulfate 
ATCC American Type Culture Collection 
ATP adenosine-5’-triphosphate 
AZT azidothymidine 
BCR B cell antigen receptor 
BSA  Bovine Serum Albumin  
°C degree Celcius 
ca. circa 
CMV cytomegalovirus 
CT cytoplasmic tail 
DMEM Dulbecco’s modified Eagle medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP  Deoxyribonucleotide  
DTT dithio-1,4-threithol 
ECACC European Collection of Cell Cultures 
ECL enhanced chemiluminescence 
E. Coli Escherichia Coli 
EDTA ethylene-diamine-tetra-acetate 
e.g. for example 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor 
ER endoplasmatic reticulum 
Env envelope protein 
et. al. and others 
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F fusion protein 
FACS fluorescence activated cell sorting 
FCS fetal calf serum 
FITC fluorescence isothiocyanate 
FP fusion peptide 
g gram or gravitational acceleration 
gag group specific antigen 
GALV gibbon ape leukemia virus 
GFP green fluorescent protein 
h hour 
H hemagglutinin 
HEK Human embryonic kidney cells 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HeV Hendravirus 
HIV-1 human immunodeficiency virus-1 
HRP horseradish peroxidase 
ICLC Interlab Cell Line Collection 
IL Interleukin 
kDa kilodalton 
l liter 
LB Luria-Bertani 
LV lentiviral vector 
LTR long terminal repeats 
m milli- 
M Molar 
mAb monoclonal antibody 
MFI mean fluorescence intensity 
µ micro- 
min minute 
MLV murine leukemia virus 
MOI multiplicity of infection 
MV measles virus 
n nano- 
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NEB New England Biolabs 
NiV Nipahvirus 
OD optical density 
p.a. pro analysis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PE R-Phycoerythrin 
PEI polyethylenimine 
pol polymerase 
ψ psi-packaging signal of retroviral genomic RNA 
RNA ribonucleic acid 
rpm rounds per minute 
RPMI culture medium developed in the “Roswell Park Memorial Institute” 
RT room temperature 
scAb single-chain antibody 
SDS sodium dodecyl sulfate 
sec seconds 
SFFV spleen focus forming virus 
SIV simian immunodeficiency virus 
SLAM signaling lymphocyte activation molecule 
SP signal peptide 
TBF Tupaia baby fibroblasts 
TBS Tris-buffered saline 
TEMED tetramethylethylenediamine 
TM transmembrane domain 
TPMV Tupaia paramyxovirus 
Tris tris(hydroxymethyl)aminomethane 
t.u. transducing units 
U unit 
UV ultraviolet 
V volt 
VSV-G vesicular stomatitis virus-glycoprotein 
WB Western Blot 
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3. INTRODUCTION 
3.1. Lentiviral vectors for gene therapy 
Gene therapy is the treatment of a disease or a medical disorder by delivering genes 
into appropriate cells (Verma and Weitzman, 2005). Lentiviral vectors (LVs) are 
becoming a more and more attractive gene transfer system for the therapy of a 
variety of diseases, as they mediate long term gene expression and transduce both 
dividing and non-dividing cells (Matrai, Chuah, and VandenDriessche, 2010). These 
properties are advantageous in many gene therapeutic applications, because they 
allow stable transduction of, for example, terminally differentiated cells, like neuronal 
cells. LVs can accommodate large transgenes (up to ~ 10 kb) (Kaiser, 2003) and for 
example, change gene expression by introducing a therapeutic gene or kill a certain 
cell type by introducing suicide genes. Another strategy for therapy is to mediate 
antigen expression and presentation by transduction of dendritic cells with lentiviral 
vectors to activate the immune response of the host. Other possible target tissues 
include different areas of the brain, liver, muscle cells and bone marrow. While some 
cell types, mainly hematopoietic stem cells, can be transduced ex vivo and returned 
to the patient (Cartier et al., 2009), other cell types, like brain cells, can currently only 
be reached by direct injection of the viral vector.  
Vectors based on retroviruses have already been tested in clinical trials. In the year 
2000, eleven children with X-linked severe combined immunodeficiency (X-SCID) 
were cured by transduction of bone marrow with a vector based on the mouse 
leukemia virus (MLV), leading to correction of the defective gene (Cavazzana-Calvo 
et al., 2000). Unfortunately, some of the children developed leukemia due to 
insertional mutagenesis (Kaiser, 2003). Lentiviral vectors have been shown to 
harbour a lower risk of mutagenesis from transgene integration and therefore, they 
may substitute retroviral vectors in the future (Hematti et al., 2004; Modlich et al., 
2009).  
Currently, lentiviral vectors are applied in about 2.3 % of clinical trials 
(http://www.wiley.com//legacy/wileychi/genmed/clinical/), and the number is 
increasing. Although these vectors are a promising tool, vector specificity and safety 
have to be improved. Targeted vectors that can be systemically administered to the 
patient and still only transduce selected cells would be a major improvement in vector 
technology (Waehler, Russell, and Curiel, 2007).  
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3.1.1. Vector design 
The first retroviral vectors developed for gene transfer were based on γ-retroviruses 
such as the murine leukemia virus (MLV) (Mann, Mulligan, and Baltimore, 1983). 
These retroviral vectors were also used in the first approved human gene therapy 
trial to correct severe combined immunodeficiency (SCID) (Anderson, Blaese, and 
Culver, 1990; Blaese et al., 1993; Levine and Friedmann, 1991). In recent years, 
lentiviral vectors in contrast to γ-retrovirus-based vectors have become more and 
more popular. They are derived from lentiviruses that, like γ-retroviruses, belong to 
the Retroviridae, a family of enveloped single-stranded (ss) RNA viruses of around 
80 to 120 nm diameter (Vogt and Simon, 1999). The best known example of 
lentiviruses is the human immunodeficiency virus-1 (HIV-1). The genome consists of 
two copies of positive single- stranded RNA which, together with the viral replication 
enzymes, is enclosed by the capsid (Fig. 1). The viral envelope, that surrounds the 
capsid, is composed of the host cell membrane and complexes of the viral envelope 
protein Env which mediate attachment of the virus to its receptors on the host cell 
surface, enabling pH-independent fusion of the viral and cellular membrane (Freed, 
2007).   
 
               
 
 
Figure 1: Schematic drawing of the lentivirus HIV-1 
The two ssRNA molecules that are associated with the reverse transcriptase are indicated. They are 
surrounded by the capsid which is composed of the capsid protein p24. The membrane-associated 
matrix underlies the cell-derived lipid membrane with the inserted viral envelope proteins gp41 and 
gp120. (modified from http://www.charite.de/maximalmethodisch/e139/e84/hiv1.jpg 
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The lentiviral genome is more complex than that of other retroviruses. It is organized 
mainly in the gag, pol and env genes but compared to simple retroviruses, 
lentiviruses have additional accessory genes that regulate viral gene expression, 
assembly and replication (Freed, 2007), namely tat, rev, nef, vif, vpu and vpr (Fig. 2). 
The Gag gene encodes the structural proteins including the membrane associated 
matrix protein, the core forming capsid protein and the viral RNA-binding 
nucleocapsid protein. The viral enzymes that accompany the ssRNA are encoded by 
the pol gene, including the reverse transcriptase, which transcribes the viral RNA to 
DNA, the integrase, that catalysis integration of the proviral DNA into the host 
genome and the protease which is responsible for gag-pol cleavage and virion 
maturation (Katz and Skalka, 1994). The env gene encodes the viral envelope. 
 
 
 
 
Figure 2: Schematic representation of the MLV and HIV-1 genome 
A: Proviral structure of MLV genome; B: Proviral structure of HIV-1 genome LTR: long terminal 
repeats; ψ: encapsidation signal psi (modified from (Hu and Pathak, 2000)) 
 
 
On both ends of the retroviral genome there are redundant sequences called long 
terminal repeats (LTRs) (Coffin, 1996; Vogt, 1997) that can be further divided into U3 
(unique 3’), R (repeat) and U5 (unique 5’) regions (Fig. 2). The viral promoter, 
transcription enhancers, a transcription termination signal and polyadenylation 
signals are located in these regions. The LTRs also contain short sequences, the 
attachment sites that are important for integration of the viral DNA into the host 
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chromosomes (Coffin, 1996). The packaging signal ψ or encapsidation signal 
contains sequences that interact with viral proteins to mediate packaging of the 
genomic RNA into newly formed virions (Watanabe and Temin, 1982).  
The life cycle of lentiviruses can be separated into different steps (Fig. 3): First, the 
virus binds to its receptors via the glycoproteins of the viral envelope and fuses with 
the cell membrane. Afterwards, the virus is uncoated and the viral core containing 
genomic RNA is released into the cytoplasm where the viral ssRNA is reverse 
transcribed into a dsDNA copy. The dsDNA within the core is then actively 
transported to the nucleus (Bukrinsky et al., 1993) and integrated into the host 
genome as a provirus. This active transport is one of the major advantages of 
lentiviruses over retroviruses, because this is the reason why they are able to infect 
not only dividing but also non-dividing cells. In contrast, other retroviruses are 
dependent on cell division and dissolution of the nucleus to integrate their reverse 
transcribed dsDNA copies. After integration of proviral DNA, the cellular transcription 
and translation machinery is used to express the viral genes and to generate RNA 
encoding all viral proteins. This newly generated viral RNA is packaged and a new 
virus is assembled which leaves the host cell by budding.   
 
 
                            
 
 
Figure 3: Life cycle of HIV-1 
The virus binds to the cell surface and fuses with the host membrane. After entering the host cell, 
reverse transcriptase produces proviral double-stranded DNA that is transported to the nucleus. The 
DNA is integrated and viral RNA is synthesized for the production of viral proteins. At the cell 
membrane, assembly occurs and the virus leaves the cell by budding. (Hoggard and Owen, 2003) 
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Due to the lentiviral life cycle, it is obvious why they are becoming more and more 
popular as vectors in gene therapy. They are very efficient in gene transfer, and 
integration of the transferred genes into the host genome allows long-term gene 
expression. Vectors derived from lentiviruses are replication-deficient and can carry 
any gene of interest into a target cell, a process called transduction. 
When generating lentiviral vectors some important safety issues have to be 
considered. First, all non-essential genes, like genes for the accessory proteins and 
for virulence should be removed from the vector sequence. Second, sequences 
necessary for vector RNA synthesis, packaging, reverse transcription and integration 
of cDNA should be split onto a different plasmid than elements encoding the viral 
enzymes and structural proteins. These so called cis- and trans-acting sequences 
should have a minimum of sequence overlap to reduce the risk of homologous 
recombination and thereby generation of replication-competent vectors. In trans, the 
genes for the polyproteins gag and pol have to be provided. The resulting plasmid is 
called packaging vector (Fig. 4, A). In cis-acting sequences, including the 5’ and 3’ 
LTR, the packaging signal ψ and the gene of interest which is under the control of a 
chosen promoter, are present on a plasmid called transfer vector (Fig. 4, B). The 
genes encoding the envelope proteins are provided on a third plasmid, the envelope 
vector (Fig. 4, C). The packaging vector and the envelope vector plasmids both lack 
a functional ψ-site and are therefore not packaged into vector particles.  
The packaging vector plasmids are divided into “generations” depending on the viral 
sequences provided (Fig. 4, A). The first generation plasmid contains the gag and pol 
sequences, the viral regulatory genes tat and rev and all accessory genes (vif, vpr, 
vpu and nef). To improve lentiviral vector safety, in the second generation the four 
accessory genes were removed, leaving only the regulatory genes tat and rev 
(Zufferey et al., 1997). Tat protein increases the level of viral RNA during production 
by activating the LTRs and Rev protein interacts with viral RNA containing a Rev 
Responsive Element (RRE) to be transported from the cell nucleus to the cytoplasm. 
In the third generation, the rev gene is split from the gag and pol sequences and 
expressed from a separate plasmid (Dull et al., 1998).  
The transfer vector plasmids can be modified by deleting promoter/enhancer 
sequences in the U3 region of the 3’ LTR, resulting in a self-inactivating (SIN) vector 
(Miyoshi et al., 1997; Zufferey et al., 1997) (Fig. 4, B). During reverse transcription, 
this deletion is reproduced in the 5’ LTR and therefore transcription of the provirus is 
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inactivated and no packagable RNAs can be produced (Fig. 4, D and E). This 
modification decreases the risk of replication competent lentiviruses. Additionally, 
LTR-mediated insertional activation of proto-oncogenes is reduced due to the 
deleting of the enhancer elements. One of the disadvantages of this vector system is 
the low transcription activity of the internal promoter of the transgene, in contrast to 
the promoter/enhancer sequences of the LTR. To overcome this problem and to 
further improve vector safety, the choice of the promoter is very important, for 
example, to set the transfer gene under control of an inducible or a cell-specific 
promoter (transcriptional targeting).  
 
 
Figure 4: Gene delivery system based on lentiviral vectors 
A-C: Different plasmids for production of lentiviral vectors and genes they contain are shown.   
D: Schematic drawing of the RNA that the produced vector contains. E: Sequences integrated by the 
vector in host genome (provirus). CMV: cytomegalovirus immediate-early promoter; EF1α: human 
elongation factor 1-α promoter; gag: 5' portion of gag gene containing dimerization/packaging signals; 
PBS: primer binding site; DIS: dimerization signal; SD: splice donor site; SA: splice acceptor site; ψ: 
packaging signal; cPPT: central polypurine tract; CTS: central termination sequence; RRE: Rev 
response element; PPT: polypurine tract; pA: polyadenylation signal; ΔU3: SIN deletion in U3 region of 
3' LTR; P: internal promoter for transgene expression; WPRE: woodchuck hepatitis virus (WHV) post-
transcriptional regulatory element. (Pluta and Kacprzak, 2009) 
 
 
For the production of lentiviral vectors, the packaging plasmid, the transfer plasmid 
carrying the transgene, e.g. an eGFP-encoding gene and a plasmid encoding the 
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envelope are transiently co-transfected in packaging cells, most commonly these are 
human embryonic kidney (HEK) 293T cells (Fig. 5) (Naldini et al., 1996).  
Vector particles are released into the supernatant of the producer cells that have 
incorporated the RNA of the transfer vector but do not contain the genetic material for 
the core and envelope proteins. Since the viral vectors bud from the cell membrane, 
the viral envelope is composed of the cellular lipid-bilayer and the incorporated viral 
envelope proteins. The vector-containing cell supernatant can be used either 
immediately or concentrated for transduction.     
 
 
 
 
Figure 5: Production of lentiviral vectors 
Packaging cells (here 293Tcells) are transfected with a packaging plasmid, a transfer vector plasmids 
and a plasmid encoding an envelope protein. After 24-48 hours, the viral particle containing 
supernatant of the producer cells is harvested and used for transduction of target cells. Transduced 
cells are finally analyzed for transgene expression, e.g. GFP. GFP: green fluorescence protein 
 
 
Tropism of lentiviral vectors is determined by the viral envelope protein. It interacts 
with its receptor on the target cell membrane and triggers fusion. Since the HIV-1 
wildtype envelope protein has only restricted tropism, glycoproteins derived from 
other viruses are often used for lentiviral production.  
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3.1.2. Pseudotyping of lentiviral vectors 
One of the great advantages of lentiviral vectors is that their natural tropism can be 
altered by exchanging the native envelope protein with glycoproteins from different 
viruses, a process called pseudotyping (Fig. 6). 
 
 
     
 
Figure 6: Pseudotyping of lentiviral vectors 
A lentivirus binds to a receptor via specific glycoproteins. This interaction determines the host range of 
the virus. Pseudotyping means changing the tropism by replacing the viral attachment glycoprotein 
with that of a different virus. SU: surface subunit; TM: transmembrane subunit; Env: envelope 
glycoprotein (modified from (Waehler, Russell, and Curiel, 2007)) 
 
 
Lentiviral vectors are highly permissive for incorporation of glycoproteins derived 
from other viruses (Cronin, Zhang, and Reiser, 2005; Schnierle et al., 1997). The 
pseudotyped particles possess the ability to transduce target cells of the virus from 
which the envelope protein was derived. Consequently, pseudotyping allows infection 
of target cells that the virus does not naturally infect. 
The key event for pseudotyping lentiviral vectors was the observation made when 
HIV-1 was produced in cells infected with different viruses, e.g. amphotropic murine 
leukemia virus (MLV) (Chesebro, Wehrly, and Maury, 1990; Spector et al., 1990) or 
herpes simplex virus (HSV) (Zhu, Chen, and Huang, 1990). The resulting virions 
showed an expanding host range, suggesting that envelope proteins of MLV and 
HSV were incorporated.  
The molecular events occurring during pseudotyping of lentiviral vectors are still not 
fully understood. There are two mechanisms proposed that lead to incorporation of 
viral proteins in viral vectors, an active and a passive mechanism. For active 
incorporation, direct interactions of the cytoplasmic tail (CT) of the envelope protein 
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and components of the virion core or indirect interactions via cellular factors with viral 
gag proteins are required (Murakami and Freed, 2000a; Murakami and Freed, 2000b; 
Swanstrom and Wills, 1997). During passive incorporation, a nonspecific interaction 
between the cytoplasmic tail and the viral core takes place, assuming that there is no 
steric incompatibility of the CT with viral assembly and that there are sufficient 
amounts of envelope proteins presented at the site of virus budding (Swanstrom and 
Wills, 1997). Lipid rafts play an important role in pseudotyping. It was shown that 
many viruses such as C-type retrovirus, Lentivirus and Paramyxoviurs reassemble 
their envelope in these microdomains of the plasma membrane (Pickl, Pimentel-
Muinos, and Seed, 2001). As a consequence, the envelope proteins of other viruses 
and cellular components are incorporated into viral particles during co-infection.   
Today, the most common envelope protein used for pseudotyping is the glycoprotein 
of vesicular stomatitis virus, VSV-G. The possibility of pseudotyping LVs with VSV-G 
was first demonstrated 1996 independently by three different groups (Akkina et al., 
1996; Naldini et al., 1996; Reiser et al., 1996). VSV-G-pseudotyped vectors have a 
high stability, a broad host range and high titers can be generated. However, since 
the aim of viral gene therapy is to target only specific cells or tissues, the broad 
tropism of VSV-G can be disadvantageous. For specific targeting of cells, 
glycoproteins of viruses that naturally infect only one cell type are often used. 
Examples are transduction of neuronal tissue by lyssavirus-pseudotyped LVs 
(Desmaris et al., 2001; Watson et al., 2002) or airway epithelium transduction by 
filovirus–pseudotypes (Chan et al., 2000; Kobinger et al., 2001).  
One of the problems of pseudotyping LVs is that often the titers reached by 
pseudotyped lentiviral vectors are very low due to insufficient incorporation of 
heterologous glycoproteins. To overcome this problem the cytoplasmic tails of some 
glycoproteins have to be modified. As mentioned before, CT interactions with the 
viral core may play an important role in glycoprotein incorporation. It was shown that 
most mammalian and avian retroviruses such as HIV, MLV and ALV (avian leukemia 
virus) require proteolytic cleavage of the R-peptide, a short amino acid sequence (16 
aa) at the C-terminus of CT of the envelope glycoprotein for activation (Bobkova et 
al., 2002; Green et al., 1981; Henderson et al., 1984; Schneider et al., 2011). 
Pseudotyping of retroviral vectors using paramyxovirus glycoproteins requires 
truncation of the proteins’ cytoplasmic tails. The fusion (F) and attachment (H) 
proteins of the measles virus can only be incorporated into lentiviral vectors when 
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their cytoplasmic tails are truncated (Funke et al., 2008a; Funke et al., 2009). In 
another example the F (fusion) and HN (hemmagglutinin-neuraminidase) protein of 
Sendai virus were efficiently incorporated into a simian immunodeficiency virus (SIV) 
derived vector after truncation of the F protein cytoplasmic tail. Additionally, in this 
system the CT of the SIV envelope protein was added to the CT of the 
hemmagglutinin-neuraminidase (Kobayashi et al., 2003). Recently, another study 
was published where a chimeric glycoprotein was used to pseudotype a lentiviral 
vector. In this study, the cytoplasmic tail of rabies virus glycoprotein (RVG) was 
replaced with the cytoplasmic region of VSV-G. The resulting vectors showed an 
increase in transduction efficiency due to higher levels of glycoprotein incorporation 
and efficiently transduced the central nervous system of rats in vivo (Carpentier et al., 
2011).  
To date, glycoproteins of many virus families have been used for pseudotyping. But 
often, the specificities of the used glycoproteins are not sufficient to transduce only 
one certain cell type. To further narrow the tropism of viral vectors for gene therapy, 
additional modifications are necessary.  
 
3.1.3. Targeting strategies for lentiviral vectors  
Lentiviral vectors pseudotyped with heterologous glycoproteins allow transduction of 
a certain cell type or tissue, dependent on the tropism of the virus the glycoproteins 
are derived from. Since many viruses naturally infect more than one kind of tissue or 
cell type, different techniques to further increase efficiency and specificity of vectors 
were developed. One of the targeting strategies to restrict tropism is the use of 
specific promoters that are active only in target cells, a process called transcriptional 
targeting (Waehler, Russell, and Curiel, 2007). Examples for the use of LVs with cell 
type specific promoters are expression of a transgene in endothelial cells (De Palma, 
Venneri, and Naldini, 2003), in retinal cells (Miyoshi et al., 1997) or liver tissue 
(Oertel et al., 2003; VandenDriessche et al., 2002). 
Another strategy is the development of protease-activatable viral vectors. For 
targeting, a polypeptide is fused to the envelope proteins that blocks attachment or 
fusion of the vector. Specific proteases on the cell surface are required that cleave 
the inhibitory peptide, resulting in gene transfer into the target cell (Szecsi et al., 
2006).  
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One of the most desirable strategies remains transductional targeting, which means 
targeting on the entry level of the viral vector. This technique leaves other tissues or 
cells completely unaffected and can be achieved for example by the insertion of cell-
type specific ligands or other molecules into the viral envelope, like growth factors 
(EGF), single chain antibodies (scAbs), cytokines or even receptors. The most 
common approach to alter the tropism of a lentiviral vector is the use of single chain 
antibodies. These molecules consist of the variable regions of one heavy and one 
light chain of an immunoglobulin that are connected with a serine-glycine linker and 
have the same specificity as the original molecule they were derived from.  Lentiviral 
vectors pseudotyped with Sindbis virus glycoproteins are an example for targeting 
using antibodies. The envelope of Sindbis virus consists of the E1 and E2 protein, 
which are responsible for attachment and fusion. Targeting was achieved by a 
monoclonal antibody that was non-covalently bound to the glycoproteins of the viral 
envelope (Morizono et al., 2005). Since Sindbis virus uses more than one receptor 
for cell entry, in this approach the receptor binding sites of the E2 protein were 
mutated, resulting in an engineered virus, that is unable to recognize its natural 
receptor. One disadvantage of this system is the pH-dependent membrane fusion 
and the vector instability due to the non-covalent bond between the antibody and the 
glycoproteins. Sindbis virus enters the cell by receptor-mediated endocytosis which is 
required for E1-E2 activation. Subsequent fusion is induced by low pH in the 
endosomes.  
Recently, efficient targeting of lentiviral vectors pseudotyped with glycoproteins of a 
paramyxovirus, the measles virus (MV) F (fusion) and H (attachment) proteins has 
been reported (Anliker et al., 2010; Frecha et al., 2008; Funke et al., 2008a; Funke et 
al., 2009; Munch et al., 2011). In contrast to Sindbis virus, the envelope proteins of 
MV mediate pH-independent membrane fusion and endocytosis for glycoprotein 
activation is not required. Targeting of MV is based on the covalently bond of 
specificity domains on the viral hemagglutinin (Cattaneo et al., 2008; Navaratnarajah, 
Leonard, and Cattaneo, 2009). However, to achieve full targeting, modifications of 
the H protein to avoid binding to its natural receptors CD46, SLAM and the recently 
identified nectin 4 are necessary (Nakamura et al., 2005; Noyce et al., 2011; 
Vongpunsawad et al., 2004). A potential disadvantage of the MV system is the 
presence of neutralizing antibodies in nearly all patients, either by previous infection 
with wild-type virus or by vaccination. In an animal colon carcinoma model, the 
 Introduction  
 
 
 
17 
therapeutic effect of oncolytic MV vectors was abrogated in animals vaccinated 
against MV; however when the MV glycoproteins were replaced by those of the 
related animal paramyxovirus Canine distemper virus (CDV), the oncolytic effect was 
restored (Miest et al., 2011).  
Nevertheless, glycoproteins of measles virus have great potential to pseudotype 
lentiviral vectors, since their fusion and attachment functions are separated into two 
proteins and retargeting can be achieved by displaying small molecules on the H 
protein. It has to be investigated, if other paramyxovirus envelope proteins, for 
example of non-human viruses that will not be neutralized by preexisting antibodies 
in patients, can also be targeted and used to pseudotype lentiviral vectors.  
 
3.2. Paramyxoviruses 
The Paramyxoviridae are a family within the order Mononegavirales. They are 
enveloped negative-strand RNA viruses that are widespread among humans and 
animals. The family of Paramyxoviridae is further classified into the two subfamilies 
Paramyxovirinae and Pneumovirinae. Genera of Paramyxovirinae are Respirovirus, 
Rubulavirus, Avulavirus, Morbilivirus and Henipavirus. Pneumovirinae contains two 
genera, Pneumovirus and Metapneumovirus. Each of the five genera of 
Paramyxovirinae includes species that are highly pathogenic for humans. Most 
prominent examples are the measles virus, which is a Morbilivirus, mumps virus 
(Rubulavirus) and Sendai virus (Respirovirus). In recent years, the Hendra and Nipah 
viruses (Henipaviruses) were identified which cause deadly diseases in animals and 
humans. The most famous member of Pneumovirinae is the Human respiratory 
syncytial virus (HRSV) which is often the causative agent for respiratory infections in 
young children (Counihan et al., 2001). There are several species of the 
paramyxoviruses that have not yet been classified into genera, for example J virus, 
Mossmann virus and the Tupaia paramyxovirus (Lamb, 2007). 
All members of this virus family have a similar viral structure (Fig. 7). They are 
enveloped viruses with a diameter of 150 to 300 nm and in some cases even greater 
than 1 µm (Goldsmith et al., 2003). The envelope is a cell-derived lipid bilayer in 
which two kinds of virus-derived glycoproteins are embedded, the attachment protein 
and the fusion protein. The attachment glycoproteins are the HN (hemagglutinin-
neuramidase) for Respiroviruses, Rubulaviruses and Avulaviruses, the H 
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(hemagglutinin) for Morbilliviruses and the G (glycoprotein) for Henipaviruses and 
members of Pneumovirinae. Dependent on the genera, the attachment proteins 
possess hemagglutination activity only (H), or hemagglutination and neuraminidase 
activity (HN) or none of these activities (G). The other glycoprotein is the F (fusion) 
protein that mediates fusion of the viral envelope with the cell membrane. Fusion 
occurs pH-independently. The glycoproteins are abundantly incorporated into the 
envelope and form spike-like complexes. The genome is enclosed by the envelope 
and consists of a non-segmented, negative RNA strand which is bound to the 
nucleocapsid to form helical structures called ribonucleoproteins (RNPs). The matrix 
(M) protein which organizes virus assembly and maintains viral structure is 
assembled between the envelope and the nucleocapsid.  
 
                                      
                               
 
Figure 7: Schematic representation of a paramyxovirus 
The M protein is underlying the inner surface of the lipid envelope in which the viral glycoproteins (HN, 
H and F or G) are embedded. The RNP is associated with the M protein and contains the negative-
strand single-stranded RNA genome, the viral RNA-dependent RNA-polymerase and the N and P 
proteins. HN: hemagglutinin-neuraminidase; H: hemagglutinin; G: glycoprotein; F: fusion protein; M: 
matrix protein; RNP: ribonucleoproteins (Harrison, Sakaguchi, and Schmitt, 2010)              
 
 
The life cycle of paramyxoviruses (Fig. 8) starts with binding of the virus to a receptor 
molecule on the surface of a target cell, followed by fusion of the viral membrane with 
the target cell membrane. Afterwards, the virion content including the RNP is 
released into the cytoplasma of the target cell and viral transcription starts. The viral 
RNA-dependent RNA polymerase complexes produce individual messenger RNAs 
from the negative-sense viral genomic RNA that are then translated into viral 
proteins.   
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Genes closest to the 3‘ end are transcribed more abundantly than those towards the 
5‘ end, because the RNA polymerase often dissociates from the RNA genome and 
has to reenter it at the 3‘ end. As a result, there is a gradient of gene expression 
regulated by the position of each gene relative to the single promotor (Cattaneo et 
al., 1987a; Whelan, Barr, and Wertz, 2004). The negative-sense viral genomic RNA 
not only serves as a template for transcription but also for replication. First, positive-
sense antigenomes are produced that are followed by production of negative-sense 
genomes from the antigenome template. The newly synthesized genomic RNA 
together with the newly produced viral proteins is transported to the cell membrane 
where assembly occurs and new viruses leave the infected cell by budding.  
 
 
      
 
Figure 8: Life cycle of paramyxoviruses 
After attachment and fusion of the virus with the cell membrane, the ss(-) RNA genome is released 
and transcribed into positive-stranded messenger RNA (mRNA) which is then translated into the viral 
proteins. For virus replication, a positive-stranded antigenome is produced that serves as a template 
for viral ss(-)RNA genome. Transcription and replication occur in the cytoplasm. Viral structure 
proteins and RNPs containing RNA genome assemble together and leave the infected cell by budding. 
M: matrix protein; F: fusion protein; HN: hemagglutinin-neuraminidase; H: hemagglutinin; G: 
glycoprotein; N or NP: nucleocapsid protein; P: phosphoprotein; L: large protein: V: protein V; C: 
cellular protein; SH: strongly hydrophobic protein (Harrison, Sakaguchi, and Schmitt, 2010) 
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3.2.1. The Tupaia paramyxovirus 
The Tupaia paramyxovirus (TPMV) was first isolated in 1999 from spontaneously 
degenerating primary kidney cells of an apparently healthy Southeast Asian tree 
shrew (Tupaia belangeri) (Tidona et al., 1999). Tree shrews are related to 
insectivores and primates, but are classified as a separate mammalian order 
(Scandentia). These animals are phylogenetically more closely related to primates 
and humans than any other laboratory animal. This makes them very interesting as 
an animal model for human diseases caused by viral infections (Darai et al., 1978; 
Xie et al., 1998).  
The host range of TPMV is restricted to Tupaia cells, it does not grow in any other 
cell line tested so far. The receptor for cell entry of the virus is not known. Infection of 
Tupaia cells with TPMV results in a cytopathic effect including multinucleated 
syncytia followed by cell lysis. Viruses released in the supernatant of infected cells 
reach titers around 105 PFU/ml. There is no serological cross-reactivity detected 
between TPMV and other paramyxoviruses including measles virus, suggesting that 
TPMV is antigenetically distinct from these viruses.  
The TPMV genome shows the typical paramyxovirus gene order N-P/C//V-M-F-H-L 
(Fig. 9) whereas all genes are separated by the nontranscribed trinucleotide CUU. 
The complete genome consists of 17,904 nucleotides which is larger than those of 
most paramyxoviruses (Springfeld et al., 2005).  
 
 
 
Figure 9: Gene order of the Tupaia paramyxovirus 
The 17,904-nucleotide single-stranded TPMV antigenome is represented by the black bar. The arrows 
indicate the positions of the open reading frames (ORFs) of the N, P, C, V, M, F, H and L protein. The 
small vertical bars mark the positions of the intergenic sequences. (Springfeld et al., 2005) 
 
 
The six genes of the TPMV genome are flanked by non-coding sequences, a control 
region called leader at the 3’ end and a sequence known as trailer at the 5‘ end 
(Lamb, 2007).In general, for paramyxoviruses applies that the N gene encodes the 
nucleocapsid protein, which is the first gene transcribed from the viral genome and 
which interacts with viral RNA. The P gene contains overlapping open reading 
frames (ORFs) and encodes the proteins P (phosphoprotein), V and C. The 
phosphoprotein has an essential role in RNA-polymerase activity and interacts with 
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the L and N proteins. The V and C proteins are accessory proteins that probably 
counteract host antiviral responses (Goodbourn and Randall, 2009; Ramachandran 
and Horvath, 2009).  
The L (large) gene encodes the viral RNA-dependent RNA-polymerase, which binds 
to the N and P proteins to from ribonucleoproteins (RNPs). The matrix (M) protein 
encoded by the M gene is associated with the nucleocapsid, interacts with the 
cytoplasmic tails of the glycoproteins F and H and initiates virus assembly and 
budding. The glycoproteins encoded by the genes F and H are part of the viral 
envelope and mediate attachment and fusion to the target cell. Because of their 
essential role in this thesis they are described in more detail later on.   
Analysis of the nucleotide sequence of the N and P gene revealed typical 
characteristics of the subfamily Paramyxovririnae and provided sufficient evidence 
that TPMV is phylogenetically related to the Henipaviridae and the Morbiliviridae. But 
since there are only low amino acid sequence homologies among TPMV, 
Henipaviridae and other known paramyxoviruses, there is the assumption that TPMV 
represents a new genus within the Paramyxovirinae (Fig. 10) (Tidona et al., 1999).    
 
                     
 
 
Figure 10: Phylogenetic tree of Paramyxovirinae subfamily members 
Relationship of Paramyxovirinae subfamily members is based on the alignment of the amino-acid 
sequence of the N gene of selected Paramyxovirinae subfamily members. Morbillivirus genus: MeV 
(measles virus), CDV (canine distemper virus); Henipavirus genus: HeV (Hendra virus), NiV (Nipah 
virus); Respirovirus genus: SeV (Sendai virus), hPIV3 (human parainfluenza virus 3); Avulavirus 
genus: NDV (Newcastle disease virus); Rubulavirus genus: hPIV2 (human parainfluenza virus 2), MaV 
(Mapuera virus), MuV (mumps virus), PIV4a (parainfluenza virus 4a), PoRV (porcine rubulavirus), SV5 
(simian parainfluenza virus 5), SV41 (simian parainfluenza virus 41); and unclassified viruses SalV 
(Salem virus) and TPMV (Tupaia paramyxovirus). (modified from (Eaton et al., 2006))  
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3.2.2. Glycoproteins of the Tupaia paramyxovirus 
As already mentioned before, the glycoproteins of TPMV, namely F and H, are 
responsible for attachment and fusion of the virus with the target cell. The H protein 
is a type II transmembrane protein with a length of 665 amino acids. Due to the ability 
of TPMV virions to hemagglutinate Tupaia erythrocytes the protein is named 
hemagglutinin (H). It has no neuraminidase activity (Tidona, 1999). The protein is 
glycosylated at three N glycosylation sites and the corresponding molecular mass is 
~ 80 kDa (Springfeld et al., 2005). Compared to other paramyxovirus attachment 
proteins, there is only low sequence identity (< 20%) and the cytoplasmic tail of 
TPMV H is unusually long (94 amino acids). The TPMV H protein mediates 
attachment of the virus to the cell surface through interactions with an unknown 
receptor.  
A few years ago, it was shown that the TPMV H protein can be targeted to a 
designated cell type by displaying a single chain antibody (scAb) on the ectodomain 
(Springfeld et al., 2005), in a similar way as it had previously been shown for measles 
virus H protein (Schneider et al., 2000). Hence, it is possible to target TPMV H to 
non-Tupaia cells via respective ligands.  
In contrast to TPMV H, the F protein is a trimeric type I transmembrane protein that 
mediates fusion of the virus with the host cell membrane. It is expressed as a F0 
precursor protein with a length of 553 amino acids including a hydrophobic region, 
the signal peptide at the N-terminus. During virus maturation and after removal of the 
signal peptide, the F0 protein is cleaved by an unknown protease into an N-terminal 
F2 and a C-terminal F1 fragment. The last one contains two hydrophobic regions, a 
fusion peptide at the amino terminus and the transmembrane domain. Furthermore, 
the TPMV F protein contains four N glycosylation sites in the ectodomain, three on 
the F2 fragment and one on the F1 fragment. As mentioned for TPMV H, also for 
TPMV F the similarity to fusion proteins of other paramyxoviruses is low (33.4 % 
identity to MV, 31.8 % identity to Nipahvirus).  
Fusion of paramyxoviruses occurs at the host cell membrane, it does not require the 
low pH of the endosome to trigger fusion (Lamb, 2007). In most paramyxoviruses, 
the attachment protein interacts with the receptor and this interaction initiates 
conformational changes in the F protein, resulting in activation of the membrane 
fusion (Lamb and Jardetzky, 2007). When Tupaia cells are transfected with plasmids 
encoding TPMV H and F, the cells fuse and form large syncytia, demonstrating that 
 Introduction  
 
 
 
23 
no other virus proteins are necessary for attachment and fusion of target cells. This 
observation and the possibility to retarget the H protein in a similar way to MV H 
make the TPMV glycoproteins very interesting for pseudotyping lentiviral vectors.  
Additional advantage compared to MV glycoproteins (described in section 1.3) is that 
it is not necessary to mutate the contact residues of TPMV H since it does not 
recognize a receptor on human cells. Because TPMV glycoproteins are derived from 
an animal paramyxovirus, no neutralizing antibodies in the general population are 
expected. 
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3.3. Aim of the study 
The aim of this thesis was to generate and characterize lentiviral vectors that are 
pseudotyped with the glycoproteins of the Tupaia paramyxovirus (TPMV).  
Based on previously reported work for pseudotyping lentiviral vectors with truncated 
retargeted MV glycoproteins it was hypothesized that this system could be 
transferred to use TPMV glycoproteins for pseudotyping. It was previously shown 
that the TPMV glycoproteins can be targeted to normally non-permissive cells by 
displaying single-chain antibodies on the H protein that recognize cell surface 
antigens on target cells. Based on this work, the TPMV glycoproteins H and F had to 
be further characterized and cytoplasmic tail truncation mutants of H and F had to be 
screened. Additionally, in the same step, the retargeting possibility of the H protein 
had to be further investigated by displaying a single chain antibody against the B cell 
surface marker CD20 on the ectodomain. The contact residues responsible for 
attachment of the cell do not have to be mutated, since TPMV is restricted to Tupaia 
cells. After characterization, glycoprotein mutants that support incorporation into 
lentiviral vectors had to be identified for vector production. Furthermore, the produced 
TPMV-pseudotyped vectors had to be characterized in terms of glycoprotein 
incorporation, their ability to mediate gene transfer and gene expression and their 
stability. To increase viral titers, different vector concentration techniques had to be 
tested. In a next step, it was necessary to investigate, if the retargeted TPMV-
pseudotyped vectors were able to discriminate between target and non-target cells, 
first on different separated receptor-positive and -negative cell lines, then in a mixed 
cell population. Finally, the efficiency of CD20-retargeted vector particles to 
transduce primary human B cells needed to be examined, both for activated and 
quiescent primary B cells.  
Vectors pseudotyped with TPMV-glycoproteins would represent a major advance in 
gene therapy. Recently, retargeted vectors pseudotyped with MV glycoproteins were 
developed that allow specific cell entry to a certain cell type and transduction of 
quiescent primary human B cells. The presence of neutralizing antibodies in the 
general population due to MV vaccination or disease might limit the clinical use of 
these vectors. With TPMV-pseudotyped vectors, this problem can possibly be 
overcome as they might not be neutralized by pre-existing antibodies. 
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4. MATERIAL 
 
4.1. Instruments 
Instrument Distributor 
Analytical scales  Kern, Albstadt 
Bacterial shaker  Infors AG, Böttmingen, CH  
Blotting chamber  Bio-Rad, Munich  
Camera (Power Shot G6)  Canon, Krefeld  
Centrifuge (Multifuge 3 SR+) Heraeus, Hanau  
Centrifuge (Biofuge fresco)  Heraeus, Hanau  
Centrifuge (Biofuge pico)  Heraeus, Hanau  
Centrifuge (XL 70 Ultracentrifuge)  Beckmann, Munich  
Centrifuge (J2-HC) Beckmann, Munich 
CO2 incubator Heraeus, Hanau 
Electrophoresis chamber  Steinbrenner, Wiesenbach  
Electrophoresis power supply (EPS 3500)  Pharmacia Biotech, Freiburg 
Electrophoresis power supply (GPS 
200/400)  
Pharmacia Biotech, Freiburg 
Film cassette  Amersham, Freiburg  
Film developer  Amersham, Freiburg  
Fridge, 4°C  Liebherr, Biberach  
Gel documentation station  Bio-Rad, Munich  
Heat block  VWR, Darmstadt  
Heat block (Thermomixer Compact)  Eppendorf, Hamburg  
Horizontal shaker (Duomax 1030)  Heidolph, Kehlheim  
Hotplate / stirrer   VWR, Darmstadt  
Incubator (Function Line)  Heraeus, Hanau  
Microscope (Axiovert 40 CFL)  Carl Zeiss, Jena  
Microwave   Bosch, Stuttgart  
Multistep pipette Eppendorf, Hamburg  
Neubauer counting chamber  Carl Roth GmbH, Karlsruhe  
Nitrogen tank  Thermo Electron coorp., Erlangen  
 Material  
 
 
26 
pH meter VWR, Darmstadt  
Photometer (Nano Drop-1,000)  Peqlab Biotechnology, Erlangen  
Photometer   Amersham, Freiburg  
Pipettes  Gilson, Middleton, USA  
Scales (BL 1500 S) Satorius, Göttingen  
Scanner Epso   Epson, Meerbusch  
SDS electrophoresis chamber Bio-Rad, Munich 
Sterile bench (Class II Type A/B3)  Sterilgard, Sanford, USA  
Stand  Carl Roth GmbH, Karlsruhe  
Tabletop centrifuge (Mini Spin Plus)  Eppendorf, Hamburg  
Thermostatic water bath (WBS)  Fried Electric, Haifa, IL  
Upright freezer, 20°C (Comfort) Liebherr, Biberach  
Vortex mixer Neolab Heidelberg 
Water bath  Neolab, Heidelberg  
 
4.2. Consumables 
 
Product Distributor 
Amicon 100-ultra centrifugal filter units  Millipore, Eschborn 
Centrifuge tubes (35 ml)  Beckmann, Munich  
Cover slips  Carl Roth GmbH, Karlsruhe  
Cryo tubes (2 ml)  Greiner Bio-one, Frickenhausen  
Cuvettes  Greiner, Frickenhausen  
Disposable scalpels  Feather, Cuome, JP  
DNase / RNase free water  Invitrogen, Karlsruhe  
water Sigma, Steinheim 
Filters (0.45 μm)  Whatman, Dassel  
Gloves (Semper Guard Nitrile)  Semperit, Vienna, Austria  
Gloves (Peha Soft, Latex)  Paul Hartmann, Heidenheim  
HyperfilmTM ECL  Amersham, Freiburg  
Micro test tubes (1.5 ml, 2 ml)  Eppendorf, Hamburg  
Mouth protection  Meditrade, Kiefersfelden  
Nitrocellulose membrane  Schleicher and Schüll, Dassel  
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Parafilm   Pechinery Inc., Wisconsin, USA  
Pasteur pipettes  Brand, Wertheim  
PCR tubes (200 μl)  Eppendorf, Hamburg  
Pipette tips (10 µl, Filtertips) Nerbe Plus, Winsen  
Pipette tips (200 μl, Filtertips)  Nerbe Plus, Winsen 
Pipette tips (1000 μl, Filtertips) Nerbe Plus, Winsen 
PVDF membrane Bio-Rad, Munich 
Safelock micro test tubes (1.5 ml and 2 ml)  Eppendorf, Hamburg  
Serotological pipettes (5 ml, 10 ml, 25 ml, 
50 ml)  
 BD Biosciences, San Jose, USA  
Test tubes (15 ml and 50 ml)  Greiner Bio-one Frickenhausen 
Tissue culture dishes (10 cm and 15 cm)  Falcon, Gräfeling-Lochham  
Whatman paper  Whatman Int., Ltd., UK  
6 well tissue culture dishes Greiner Bio-one Frickenhausen 
12 well tissue culture dishes Corning Inc., NY, USA  
24 well tissue culture dishes Greiner Bio-one Frickenhausen 
48 well tissue culture dishes Corning Inc., NY, USA 
96 well tissue culture dishes Nunc, Wiesbaden  
T75 cell culture flasks Greiner Bio-one Frickenhausen 
T75 cell culture flasks Greiner Bio-one Frickenhausen 
 
4.3. Chemicals and reagents 
 
Chemicals Distributor 
Acetic acid (99%)  Sigma, Munich  
Acrylamide bisacrylamide Solution (37.5 : 1) Carl Roth GmbH, Karlsruhe  
Adenosine triphosphate (ATP)  Sigma, Munich  
Agarose  Carl Roth GmbH, Karlsruhe 
Ammonium persulfate (APS)  Carl Roth GmbH, Karlsruhe  
Ampicillin  Sigma, Munich  
Antipain Roche, Penzberg 
Aprotinin Roche, Penzberg 
Bestatin Roche, Penzberg 
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Bovine serum albumin (BSA)  Sigma, Munich  
Bromophenol blue  Sigma, Munich  
Calcium chloride  Sigma, Munich  
Chymostatin Roche, Penzberg 
Desoxynucleotides (dATP, dCTP, dGTP, 
dTTP)  
Roche, Mannheim  
Dipotassium phosphate  Applichem, Darmstadt  
Disodium hydrogen phosphate  Sigma, Munich  
DMSO (Dimethyl sulfoxide)  Sigma, Munich  
DTT (Dithiothreitol)  Sigma, Munich  
Dulbecco’s modified Eagle’s medium 
(DMEM)  
Invitrogen, Karlsruhe  
E-64 Roche, Penzberg 
EDTA (Ethylenediaminetetraacetic acid),  Sigma, Munich  
EDTA-Na2 Roche, Penzberg 
Ethanol (99%)  University Hospital, Heidelberg  
Ethidium bromide  Carl Roth GmbH, Karlsruhe  
Fetal calf serum (FCS)  Invitrogen, Karsruhe  
Glucose  Sigma, Munich  
Glycerol  Baker, Deventer, NL  
Hepes  Roth, Karlsruhe  
Histopaque®-1077 Sigma, Munich 
Hydrochloric acid (HCl) 37%  Acros Organics, New Jersey, USA  
Igepal (Nonidet NP40)  Sigma, Munich  
Isopropanol  Sigma, Munich  
LB Agar Carl Roth GmbH, Karlsruhe  
LB Medium Carl Roth GmbH, Karlsruhe  
Leupeptin Roche, Penzberg 
L-glutamine Biochrome AG, Berlin 
Lipofectamine  Invitrogen, Karlsruhe  
Pefabloc SC Roche, Penzberg 
Pepstatin Roche, Penzberg 
Phosphoramidon Roche, Penzberg 
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Loading dye solution (6x)  Fermentas, St. Leon Rot  
Magnesium chloride (MgCl2)  Merck, Darmstadt  
β Mercaptoethanol (98%) Sigma, Munich  
Methanol (100%)  Merck, Darmstadt  
Milk powder  Carl Roth GmbH, Karlsruhe 
Penicillin / Streptomycin (P/S)  Invitrogen, Karlsruhe  
Pepstatin  Sigma, Munich  
Potassium chloride (KCl)  Sigma, Munich  
Protamine sulfate Sigma, Steinbach 
Proteinase inhibitor cocktail  Roche, Penzberg  
Puromycin Sigma, Munich 
Trypsin-EDTA Invitrogen, Karlsruhe  
Sodium chloride (NaCl)  AppliChem, Darmstadt  
Sodium dodecyl sulfate (SDS)   Gerbu, Biotechnik GmbH, Gaiberg  
Sodium hydroxide (NaOH)  Sigma, Munich  
N,N,N’,N’ Tetramethylenediamine (TEMED) Carl Roth GmbH, Karlsruhe  
Tris base  Sigma, Munich  
Trypsin-EDTA solution Invitrogen, Karlsruhe  
Tween-20 Sigma, Munich  
Urea  Sigma, Munich  
 
4.4. Comercial Kits 
Kit Distributor 
DynaI® B cell negative isolation Kit Invitrogen, Karlsruhe 
EndoFree Plasmid Maxiprep Kit Qiagen, Hilden 
Enhanced Chemiluminescence (ECL) Kit Amersham Biosciences, Freiburg 
Expand High Fidelity PCR System Roche, Mannheim 
QiaPrep Plasmid Maxiprep Kit Qiagen, Hilden 
QiaPrep Plasmid Miniprep Kit  Qiagen, Hilden  
QiaQuick Gel Extraction  Qiagen, Hilden  
QiaQuick PCR Purification Kit Qiagen, Hilden 
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4.5. Solutions and buffers 
 
Blocking buffer (for Western blotting) 1x PBS  
0.1% Tween 20  
5% Milk powder 
  
PBS (10x) 1.4 M NaCl  
27 mM KCl  
100 mM Na2HPO4  
8 mM KH2PO4  
pH 6.8 
  
PBS-T 1x PBS  
0.1% Tween-20 
  
RIPA lysis buffer 150 mM NaCl 
50 mM Tris-HCl, pH 7.5 
1 % Nonidet P40 
0.5 % Sodiumdeoxycholate 
1 % sodium dodecyl sulfate 
  
SDS running buffer (10x) 0.25 M Tris-base  
1.92 M Glycine  
1% SDS 
  
TAE buffer 40mM Tris 
20mM acetic acid 
1mM EDTA. 
  
TBS 10x 175.3 g NaCl/2l 
24.2 g Tris/2l 
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TBS-T 
 
48.5 g Tris/2l, pH 7.5 
584.4 g NaCl/2l 
0.05 % Tween-20 
a.d. H2O 
  
Transfer buffer SDS-PAGE 25 mM Tris-base  
192 mM Glycine  
20% Methanol  
0.01% SDS 
  
6x SDS sample buffer 0.35 M Tris-Cl/ 
0.28 % SDS pH 6.8 
30 % Glycerol 
10 % sodium dodecyl sulfate 
9.3 % DTT 
0.012 % Bromophenol Blue 
  
All buffers were diluted in H20, unless stated otherwise 
 
 
 
4.6. Molecular components (enzymes, cytokines, oligonucleotides, 
plasmids, antibodies and sera, marker) 
 
Enzmes 
 
Enzyme Distributor 
restriction endonucleases New England Biolabs, Ipswich, MA 
T4-DNA-ligase New England Biolabs, Ipswich, MA 
High Fidelity Polymerase Roche, Mannheim 
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Cytokines 
 
Cytokines Distributor 
CD40 ligand R&D Systems, Wiesbaden 
IL-2 R&D Systems, Wiesbaden 
IL-4 R&D Systems, Wiesbaden 
IL-10 R&D Systems, Wiesbaden 
 
Oligonucleotides 
All oligonucleotides were synthesized from the company Eurofins MWG Operon. 
 
Primer 5‘  3‘ sequence 
HαCD20 S GGGGCGCGCAGGTTCAGCTGGTCCAG 
TPMV-HΔ20 S TTTGGGGGATCCATTATGTTGCAGAGCCAGAGTG 
TPMV-HΔ40 S TTTGGGGGATCCATTATGTATTCAAATCCTCCAC 
TPMV-HΔ50 S TTTGGGGGATCCATTATGGATCAAGGTATTGATG 
TPMV-HΔ60 S TTTGGGGGATCCATTATGCAACCATTATCAACTC 
TPMV-HΔ70 S TTTGGGGGATCCATTATGCGTTACTATGGAGTTAAC 
TPMV-HΔ80 S TTTGGGGGATCCATTATGAGGGTGTATAATCATTTAG 
TPMV-HΔ84 S TTTGGGGGATCCATTATGCATTTAGGGACAATC 
TPMV-H AS TTTGGGTCTAGATTACTTAGTATTAGGACATGTAC 
TPMV-F S TTTGGGGGATCCCCAAGGATGGCATCACTGCTA 
TPMV-FΔ8 AS CCCGGGTCTAGATCAATGATTCTGATGACCGTTGCTCCTGTGATG 
TPMV-FΔ18 AS CCCGGGTCTAGATCATGATGGATTACGGAGGGAGT 
TPMV-FΔ25 AS CCCGGGTCTAGATCAAACATAAGAATCCAGGAAATGGAGTTTGCT 
TPMV-FΔ32 AS CCCGGGTCTAGATCAGAGTTTGCTCCATATTTTGAATGCGTAATAGC 
TPMV-FΔ33 AS CCCGGGTCTAGATCATTTGCTCCATATTTTGAATGC 
TPMV-FΔ34 AS CCCGGGTCTAGATCAGCTCCATATTTTGAATGCGTA 
TPMV-FΔ35 AS CCCGGGTCTAGATCACCATATTTTGAATGCGTAATAGCTCACACC 
TPMV-F MV3 AS CCGGGGTCTAGATCAACGACCTCTGAATGCGTAATAGCTCACACC 
TPMV-Fflag 483 
AS 
CCCGGGTCTAGATCACTTATCATCATCATCCTTATAATCCATTGA 
TPMV-Fflag 491 
AS 
CCCGGGTCTAGATCACTTATCATCATCATCCTTATAATCCTTATC 
TPMV-Fflag 492 
AS 
CCCGGGTCTAGATCACTTATCATCATCATCCTTATAATCTTTGAA 
TPMV-Fflag 495 
AS 
CCCGGGTCTAGATCACTTATCATCATCATCCTTATAATCCAACTT 
TPMV-Fflag 498 
AS 
CCCGGGTCTAGATCACTTATCATCATCATCCTTATAATCTGCTAT 
TPMV-Fflag 499 
AS 
CCCGGGTCTAGATCACTTATCATCATCATCCTTATAATCAACAACAATCATT
GCTAT 
TPMV-Fflag 500 
AS 
CCCGGGTCTAGATCACTTATCATCATCATCCTTATAATCAAAAACAACAAT
CATTGC 
TPMV-Fflag 501 
AS 
CCCGGGTCTAGATCACTTATCATCATCATCCTTATAATCAACAATCATTGC
TATTAA 
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TPMV-Fflag 505 
AS 
CCCGGGTCTAGATCACTTATCATCATCATCCTTATAATCACCAAAAACAAC
AATCAT 
TPMV-Fflag 507 
AS 
CCCGGGTCTAGATCACTTATCATCATCATCCTTATAATCAAGTAGAGTACC
AAAAAC 
TPMV-Fflag 510 
AS 
CCCGGGTCTAGATCACTTATCATCATCATCCTTATAATCGAGCCAAAGAAG
TAGAGT 
TPMV-Fflag 513  
AS 
CCCGGGTCTAGATCACTTATCATCATCATCCTTATAATCCACACCAAAGAG
CCAAAG 
TPMV-Fflag 516  
AS 
CCCGGGTCTAGATCACTTATCATCATCATCCTTATAATCGTAATAGCTCAC
ACCAAA 
TPMV-Fflag 533 
AS 
CCCGGGTCTAGATCACTTATCATCATCATCCTTATAATCATTACGGAGGGA
GTAAAC 
TPMV-Fflag 553 
AS 
CCCGGGTCTAGATCACTTATCATCATCATCCTTATAATCTCCACTTATATCT
GTACTG 
Ala1 S TTGTTAATAGCAATGATTGCTGCTGCTGGTACTCTACTTCTTTGG 
Ala1 AS CCAAAGAAGTAGAGTACCAGCAGCAGCAATCATTGCTATTAACAA 
Ala2 S TTAATAGCAATGATTGTTGCTGCTGCTACTCTACTTCTTTGGCTC 
Ala2 AS GAGCCAAAGAAGTAGAGTAGCAGCAGCAACAATCATTGCTATTAA 
 
 
Plasmids 
name characterization source 
pCG-TPMV-H TPMV H protein under control of 
CMV promotor 
Group Dr. Springfeld 
pCG-TPMV-HαCD20 TPMV H protein with αCD20-
scAb at the C-terminus, under 
control of CMV promotor 
Group Dr. Springfeld 
pCG-TPMV-HΔ20αCD20 HαCD20 with truncated 
cytoplasmic tail and with αCD20-
scAb at the C-terminus, under 
control of CMV promotor 
this thesis 
pCG-TPMV-HΔ40αCD20 HαCD20 with truncated 
cytoplasmic tail under control of 
CMV promotor 
this thesis 
pCG-TPMV-HΔ50αCD20 HαCD20 with truncated 
cytoplasmic tail and with αCD20-
scAb at the C-terminus, under 
control of CMV promotor 
this thesis 
pCG-TPMV-HΔ60αCD20 HαCD20 with truncated 
cytoplasmic tail and with αCD20-
scAb at the C-terminus,under 
control of CMV promotor 
this thesis 
pCG-TPMV-HΔ70αCD20 HαCD20 with truncated 
cytoplasmic tail and with αCD20-
scAb at the C-terminus,under 
control of CMV promotor 
this thesis 
pCG-TPMV-HΔ80αCD20 HαCD20 with truncated 
cytoplasmic and with αCD20-
scAb at the C-terminus, tail under 
control of CMV promotor 
this thesis 
pCG-TPMV-HΔ84αCD20 HαCD20 with truncated 
cytoplasmic tail and with αCD20-
scAb at the C-terminus, under 
this thesis 
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control of CMV promotor 
pCG-TPMV-F TPMV-F protein under control of 
CMV promotor 
Group Dr. Springfeld 
pCG-TPMV-FΔ8 TPMV F with truncated 
cytoplasmic tail under control of 
CMV promotor 
this thesis 
pCG-TPMV-FΔ18 TPMV F with truncated 
cytoplasmic tail under control of 
CMV promotor 
this thesis 
pCG-TPMV-FΔ25 TPMV F with truncated 
cytoplasmic tail under control of 
CMV promotor 
this thesis 
pCG-TPMV-FΔ32 TPMV F with truncated 
cytoplasmic tail under control of 
CMV promotor 
this thesis 
pCG-TPMV-FΔ33 TPMV F with truncated 
cytoplasmic tail under control of 
CMV promotor 
this thesis 
pCG-TPMV-FΔ34 TPMV F with truncated 
cytoplasmic tail under control of 
CMV promotor 
this thesis 
pCG-TPMV-FΔ35 TPMV F with truncated 
cytoplasmic tail under control of 
CMV promotor 
this thesis 
pCG-TPMV-F MV3 TPMV F with truncated 
cytoplasmic tail under control of 
CMV promotor 
this thesis 
pCG-TPMV-F483  TPMV F protein with Flag-tag at 
indicated amino acid position, 
under control of CMV promotor 
this thesis 
pCG-TPMV-F491 TPMV F protein with Flag-tag at 
indicated amino acid position, 
under control of CMV promotor 
this thesis 
pCG-TPMV-F492 TPMV F protein with Flag-tag at 
indicated amino acid position, 
under control of CMV promotor 
this thesis 
pCG-TPMV-F495 TPMV F protein with Flag-tag at 
indicated amino acid position, 
under control of CMV promotor 
this thesis 
pCG-TPMV-F498 TPMV F protein with Flag-tag at 
indicated amino acid position, 
under control of CMV promotor 
this thesis 
pCG-TPMV-F499 TPMV F protein with Flag-tag at 
indicated amino acid position, 
under control of CMV promotor 
this thesis 
pCG-TPMV-F500 TPMV F protein with Flag-tag at 
indicated amino acid position, 
under control of CMV promotor 
this thesis 
pCG-TPMV-F501 TPMV F protein with Flag-tag at 
indicated amino acid position, 
under control of CMV promotor 
this thesis 
pCG-TPMV-F505 TPMV F protein with Flag-tag at 
indicated amino acid position, 
under control of CMV promotor 
this thesis 
pCG-TPMV-F507 TPMV F protein with Flag-tag at this thesis 
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indicated amino acid position, 
under control of CMV promotor 
pCG-TPMV-F510 TPMV F protein with Flag-tag at 
indicated amino acid position, 
under control of CMV promotor 
this thesis 
pCG-TPMV-F513 TPMV F protein with Flag-tag at 
indicated amino acid position, 
under control of CMV promotor 
this thesis 
pCG-TPMV-F516 TPMV F protein with Flag-tag at 
indicated amino acid position, 
under control of CMV promotor 
this thesis 
pCG-TPMV-F533 TPMV F protein with Flag-tag at 
indicated amino acid position, 
under control of CMV promotor 
this thesis 
pCG-TPMV-F553 TPMV F protein with Flag-tag at 
indicated amino acid position, 
under control of CMV promotor 
this thesis 
pCG-F Ala1  TPMV F protein, amino acids at 
position 499-502 replaced by 
alanins; under control of CMV 
promotor 
this thesis 
pCG-F Ala2  TPMV F protein, amino acids at 
position 498-501 replaced by 
alanins; under control of CMV 
promotor 
this thesis 
pCG-MVNSeFΔ30 MVNSe strain F protein with a 
truncated cytoplasmic tail; under 
control of CMV promotor 
kindly provided by the 
group of C.J. Buchholz, 
Paul-Ehrlich-Institut, 
Langen 
pCG-MVNSeHΔ18αCD20 MVNSe strain H protein with a 
truncated cytoplasmic tail and 
with the four point mutations 
Y481A, R533A, S548L, F549S 
and αCD20-scAb at the C-
terminus; under control of CMV 
promotor 
kindly provided by the 
group of C.J. Buchholz, 
Paul-Ehrlich-Institut, 
Langen 
pCG-MVNSeHΔ18α MVNSe strain H protein with a 
truncated cytoplasmic tail; under 
control of CMV promotor 
kindly provided by the 
group of C.J. Buchholz, 
Paul-Ehrlich-Institut, 
Langen 
pCG-MVWtFΔ30 MV Wildtype strain F protein with 
a truncated cytoplasmic tail; 
under control of CMV promotor 
kindly provided by the 
group of C.J. Buchholz, 
Paul-Ehrlich-Institut, 
Langen 
pCG-MVWTHΔ18 MV Wildtype strain F protein with 
a truncated cytoplasmic tail; 
under control of CMV promotor 
kindly provided by the 
group of C.J. Buchholz, 
Paul-Ehrlich-Institut, 
Langen 
pMD.G2 encodes VSV-G D. Trono, Tronolab, 
Switzerland 
pCMVΔR8.9 HIV-1 packaging plasmid kindly provided by the 
group of C.J. Buchholz, 
Paul-Ehrlich-Institut, 
Langen 
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pSEW HIV-1 packagable vector 
encoding GFP under control of 
the SFFV promotor 
kindly provided by the 
group of C.J. Buchholz, 
Paul-Ehrlich-Institut, 
Langen 
pcDI-EGFP encodes eGFP kindly provided by Dr. 
Sascha Bossow, NCT, 
Heidelberg 
 
 
Antibodies and sera 
name dilution source of supply 
αFecto, rabbit anti-TPMV F 
polyclonal peptide serum 
1:1000 
western blot 
PSL, Heidelberg 
αHecto, rabbit anti-TPMV-H 
polyclonal peptide serum 
1:1000 
western blot 
R. Cattaneo, Mayo Clinic, 
Rochester 
mouse anti-HIV-1 p24 mAb 1:1000 
western blot 
ZeptoMetrix 
Monoclonal Anti-Flag antibody 
produced in mouse 
1:1000 Sigma-Aldrich 
HRP-conjugated swine-anti-rabbit 
antibody 
1:2000 
western blot 
DakoCytomation, 
Glostrup/Denmark 
R-Phycoerythrin (PE) conjugated 
anti-mouse IgG (whole molecule) 
F(ab’)2 fragment 
1:50 
FACS 
Sigma-Aldrich 
PE conjugated mouse anti-human 
CD19 mAb 
1:10 
FACS 
DakoCytomation, 
Glostrup/Denmark 
PE-Cy5, FITC or PE conjugated 
mouse anti-human CD20 mAb 
1:10 
FACS 
BD Pharmingen 
FITC-conjugated mouse anti-
human CD69 mAb 
1:10 
FACS 
DakoCytomation, 
Glostrup/Denmark 
PE-Cy5, FITC or PE conjugated 
mouse IgG2b,κ isotype control 
1:10 
FACS 
BD Pharmingen 
FITC or PE conjugated mouse 
IgG1,κ isotype control 
1:10 
FACS 
BD Pharmingen 
PE conjugated mouse IgG2a,κ 
isotype control 
1:10 
FACS 
BD Pharmingen 
Serum 1, 2, 3 Neutralization-Assay kindly provided by the group 
‘Virotherapy’, NCT, 
Heidelberg 
Serum MV-negative Neutralization-Assay kindly provided by the 
Universitiy Hospital, 
Heidelberg 
 
Molecular weight markers 
DNA marker  
100 bp DNA ladder NEB, Ipswich, MA, USA 
1 kb DNA ladder NEB, Ipswich, MA, USA 
Protein marker  
Precision Plus Protein™ Standards, Dual color, 
10 – 250 kDa 
Bio-Rad, Munich 
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4.7. Bacterial strains and culture media 
Strain Distributor 
E.coli BL21 Chemically Competent Cells Stratagene, La Jolla, USA 
E.coli TOP 10 Chemically Competent 
Cells 
Invitrogen, Karlsruhe 
  
Luria-Bertani (LB) 
Bacto-Trypton      1.0 % (w/v) 
yeast extract        0.5 % (w/v) 
NaCl                     1.0 % (w/v) 
pH 7.0 
 
 
 
4.8. Cell lines and culture media  
name characterization Distributor 
HEK-293T human embryonic kidney cell line 
genetically engineered to express 
the large T antigen 
ICLC HTL04001 
HT1080 human fibrosarcoma cell line ATCC CCL-121 
HT1080-CD02 human fibrosarcoma cell line 
genetically engineered to express 
CD20 
R. Cattaneo, Mayo Clinic, 
USA 
Raji human Burkitt’s lymphoma cell 
line 
ATCC CCL-86 
K-562 human chronic myelogenous 
leukemia cell line 
ATCC CCL-243 
TBF primary Tupaia baby fibroblasts R. Cattaneo, Mayo Clinic, 
USA 
 
Culture medium for HEK-293T, HT1080, TBF 
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10 % FCS and 2 
mM L-glutamine.  
 
Culture medium for Raji, K-562 
RPMI 1640 supplemented with 10 % FCS and 2 mM L-glutamine.  
 
Culture medium for HT1080-CD20 
RPMI 1640 supplemented with 10 % FCS, 2 mM L-glutamine and 3 µg/ml puromycin.  
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4.9. Software 
Software Distributor 
Endnote  Thomson, Carlsbad, USA 
Microsoft Office  Microsoft, Unterschleißheim 
Photoshop  Adobe, San Jose, USA 
Pubmed  NIH 
Vector NTI Advance™ Software  Invitrogen, Karlsruhe 
FCS-Express V3  DeNovoSoftware, Los Angeles, USA 
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5. METHODS 
5.1. Molecular Biology 
5.1.1. Agarose gel electrophoresis 
Agarose gel electrophoresis was used to analyze DNA molecules such as PCR 
products and digested plasmids, since it separates the fragments by their size. For 
production of gels, 1 % agarose was dissolved in TAE buffer by heating the emulsion 
in a microwave until it boiled. Upon cooling, 5 µg/ml ethidium bromide was added. 
DNA samples were mixed with 8 µl sample buffer and applied to the gel. Gels were 
run at 100 V for approximately 60 min. Subsequently, DNA fragments were 
photographed under a UV lamp or isolated from the gel.    
 
5.1.2. Isolation of DNA from agarose gels 
DNA fragments were cut out of the gel under a UV lamp using a scalpel, transferred 
into a 1.5 ml reaction tube and purified using the QIAquick Gel Extraction Kit, 
according to the manufacturer’s instructions. 
 
5.1.3. Restriction analysis of DNA fragments or plasmids 
For restriction analysis, restriction enzymes from New England Biolabs (NEB) were 
used according to the manufacturer’s instructions. DNA was incubated with 10-20 
units/µg of the respective enzyme, the corresponding buffers and, if necessary, with 
0.1 volume of BSA. Reactions were incubated at the temperature optimum of the 
enzyme for 2-4 hours. Restriction samples were then applied to agarose gel 
electrophoresis.  
 
5.1.4. Polymerase chain reaction (PCR) 
PCR was performed to amplify DNA fragments for further molecular biological 
methods using a thermally stable DNA-dependent DNA-polymerase. For a typical 
PCR, the following ingredients in their appropriate amounts are necessary: 
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Ingredients Amount Final concentration 
10x polymerase buffer 5 µl 1 x 
10 mM deoxynucleotide mix (dNTP) 1 µl 0.2 mM 
Forward primer (100 µM) 1 µl 2 µM 
Reverse primer (100 µM) 1 µl 2 µM 
DNA template ~ 5 ng  
High Fidelity Polymerase 1 µl 3.5 U 
Double distilled water Ad 50 µl  
 
A typical PCR reaction was programmed as followed:  
Step Temperature Time 
Denaturation 94°C 2 min 
Denaturation 94°C 15 sec 
Primer annealing 55°C 30 sec 
Extension 72°C 90 sec 
Extension 72°C 7 min 
Hold 4°C  
 
Depending on the length and G-C content of the used primers, different annealing 
temperatures were chosen using the following formula: (TAn=69°C + 0.41 x (%GC) – 
650 / bp). 
Cloning of the unmodified TPMV H and F protein has been described previously 
(Springfeld et al., 2005). The expression plasmid pCG-TPMV-HαCD20 that encodes 
a fusion protein of TPMV H and a single-chain antibody (scAb) to human CD20 was 
generated by amplification of the open reading frame of the αCD20-scAb from the 
plasmid pCGHαCD20 (Bucheit et al., 2003) using the forward primer 5'-
GGGGCGCGCAGGTTCAGCTGGTCCAG-3' that inserts a BssHII site to the 3′ end 
of the H open reading frame and a reverse primer in the backbone of the pCG vector. 
After cutting with BssII and XbaI, the fragment was cloned into the plasmid pCG-
TPMV-HXαCEA (Springfeld et al., 2005), thereby exchanging the αCEA-scAb against 
the αCD20-scAb. TPMV H cytoplasmic tail (CT) variants were generated by PCR-
cloning using primers that deleted the desired amino acids and introduced a new 
start codon. The TPMV F CT variants and FFlag variants were constructed using 
primers that introduced a stop codon and a flag-tag at the desired position, 
20 x 
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respectively, and deleted the following amino acids. The TPMV-F MV3 expression 
plasmid was generated using a primer that introduced the three cytoplasmic tail 
amino acids (arginine - glycine - arginine) followed by a stop codon. 
All PCR reactions were performed using an PCR Express, Therm Hybai cycler. 
Subsequently, they were analyzed by agarose gel electrophoresis or frozen at -20°C.  
 
5.1.5. Ligation 
For Ligation, 50-200 ng of vector DNA was used for each reaction. The ratio of insert 
to vector DNA was 3:1. Vector and insert DNA were mixed in a volume of 10 µl and 
incubated at 45°C for 5 min. Afterwards ligation buffer and T4 DNA ligase were 
added and the reaction was incubated at room temperature for 2-5 hours. The ligated 
DNA was used immediately for transformation of bacteria or stored at -20°C.  
 
5.1.6. Transformation of bacteria  
For transformation, chemically competent E. Coli bacteria were thawed on ice and 1 
µl DNA or for ligations, the whole ligation reaction were added and incubated on ice 
for 20 min. Afterwards, a heat shock of 42°C was performed for 45 sec in a water 
bath following 5 min further incubation on ice. Then, 500 µl LB medium (RT) were 
added, followed by incubation at 600 rpm, 37°C for 60 min in a thermoblock. The 
suspension was added on LB plates containing ampicillin and incubated over night at 
4°C.   
 
5.1.7. Cultivation of bacteria 
Culture plates: Bacteria were cultured on LB plates containing ampicillin (50µg/ml, 
LBAmp) by adding the bacterial suspension onto the plate and incubation overnight at 
37°C until bacterial colonies were visible. Plates with bacterial colonies were stored 
up to 6 weeks at 4°C.  
Liquid culture: Bacteria were cultured in liquid LB medium containing ampicillin (0.1 
mg/ml, LBAmp) overnight at 37°C on a shaker (~ 200 rpm).  
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5.1.8. Plasmid preparation 
For plasmid preparation from the transformed bacteria, either the QIAprep® Spin 
Miniprep kit or the EndoFree® Plasmid Maxi kit was used according to the 
instructions of the manufacturer (Quiagen).  
For extractions of small amounts of DNA (Miniprep), 5 ml LBAmp were inoculated with 
bacteria and incubated overnight at 37°C. The next day, 1.5 ml of the bacterial 
suspension were applied to a 1.5 ml reaction tube and centrifuged in for 3 min at 
5000 rpm in a table centrifuge (RT). This step was repeated three times in the same 
reaction tube. DNA extraction out of the resulting bacterial pellet was performed with 
the the QIAprep® Spin Miniprep kit.  
For extraction of large amounts of DNA (Maxiprep), 1.0 l LBAmp were inoculated with 
bacteria and cultivated overnight at 37°C. The bacteria suspension was centrifuged 
for 15min, 4°C and 6000 rpm (J2-HC, Beckman) and the resulting pellet was treated 
with the EndoFree® Plasmid Maxi kit according to the manufacturer’s instructions.  
The concentrations of the isolated plasmid DNA was determined photometrically 
(absorption 260 nm).  
 
5.1.9. DNA sequencing 
Plasmids were sequenced by the company GATC. Samples were prepared in a 
volume of 30 µl containing 50 ng/µl DNA and send together with 30 µl of appropriate 
primers (10 pmol/µl) via mail to the company.  
 
5.2. Cell Biology and virology 
5.2.1. Cultivation of cell lines 
Cells were cultivated in an incubator at 37°C, 5 % CO2 and saturated water 
atmosphere. They were passaged twice a week by removing the medium, washing 
with PBS and adding trypsin. After 1-2 minutes, fresh medium was added to the cells 
and trypsin. Out of this solution, an appropriate fraction was seeded into a new 
culture flask with fresh medium.  
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5.2.2. Freezing and thawing of cells 
For freezing, cells were trypsinised and resuspended in medium as described in 
section 2.2.1. This cell solution was then centrifuged at 900 rpm for 4 min at 4°C 
(Multifuge 3SR+), the pellet resuspended in cold freezing medium (4°C, 70 % FCS, 
15 % DMSO, 15 % DMEM or RPMI) and aliquoted in 1 ml fractions containing 
approximately 1x106 cells. Afterwards, the aliquots were stored for 24 h at -20°C, 
then for 24 h at -80°C and finally transferred into liquid nitrogen.  
Cells were thawed by putting the cryotube into a waterbath (37°C) until the cell 
suspension is liquid. Then, the cells were immediately transferred into a 15 ml 
reaction tube containing pre-warmed (37°) fresh medium. To exclude the toxic 
DMSO, the cells were centrifuged at 900 rpm for 3 min at RT (Multifuge 3SR+) and 
the pellet resuspended in 10 ml fresh medium which was then transferred into a cell 
culture flask.  
 
5.2.3. Transient transfection of cells 
293T cells, HT1080-CD20 cells and TBF cells were transient transfected using 
Lipofectamine. Twenty-four hours before transfection, cells were seeded as 
suggested by the manufacturer. One hour before transfection, medium was replaced 
by fresh medium. The plasmids were mixed with Lipofectamine and added to the 
cells. Fourty-eight hours after transfection, the cells were analyzed.  
 
5.2.4. Isolation of human peripheral blood mononuclear cells (PBMCs) 
PBMCs were isolated from human blood from Buffy coats (Blutspendedienst Hessen, 
Frankfurt a.M.) using the method of density centrifugation with Histopaque®-1077. 15 
ml of cold Histopaque (4°C) were overlaid with 25 ml of a 1 :1 mixture of human 
blood and PBS in a 50 ml Falcon tube. The mixture was centrifuged at 1,800 rpm for 
30 min (RT, no break, Multifuge 3SR+) to pellet the red blood cells and granulocytes. 
After centrifugation, a small white fraction is visible above the Histopaque that 
contains lymphocytes, monocytes and macrophages. Above this fraction, the plasma 
is present. The white lymphocyte-containing fraction was collected into a 50 ml 
Falcon (5 ml per Falcon). Then, 50 ml PBS were added to each Flacon tube followed 
by centrifugation at 1,500 rpm for 10 min at RT. The pellets were combined in one 
single Falcon tube and washed against with PBS as described before. Remaining 
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erythrocytes were lysed by adding 10 ml 0.86 % ammonium chloride and incubation 
for 20 min at 37°C. Again, the cells were washed twice with PBS as described before 
and resuspended in 50 ml PBS for determination of the cell number. Subsequent, the 
PBMCs were applied for B cell isolation.  
 
5.2.5. Isolation and activation of primary human B cells 
Primary human B cells were isolated from fresh isolated PBMCs using the Dynal B 
cell negative isolation kit (Invitrogen) as suggested by the manufacturer instructions. 
Isolated B cells were either used immediately for transduction or activated for 48 
hours in medium together with 300 ng/ml CD40 ligand, 50 ng/ml interleukin-2, 10 
ng/ml interleukin-4 and 10 ng/ml interleukin-10. Stimulated B cells were detected by 
an antibody against the activation marker CD69.  
 
5.2.6. Generation and concentration of lentiviral vectors   
For screening of all F- and H-combinations, vector particles were generated by 
transfection of 293T cells using polyethylene-imine (PEI) with 1.73 µg of the lentiviral 
transfer vector plasmid pSEW (Miyoshi et al., 1997), 1.65 µg of the packaging 
plasmid pCMVΔR8.9 (Zufferey et al., 1997) and 0.27 µg each of the TPMV-H- and F-
protein variant expression plasmids. Twenty-four hours before transfection, 2.0 x 106 
cells/well were seeded into a single well of a six-well plate. On the day of 
transfection, the medium was replaced by 0.5 ml DMEM (+1 % glutamine). The 
plasmids were mixed with 17.7 µl of 5 % (wt/vol) glucose. In a different tube, 17.7µl 
of 5 % glucose was mixed with 4 µl of 18 mM PEI. Both solutions were incubated for 
10 minutes at room temperature, then combined, mixed and incubated again at room 
temperature. After 10 minutes, the volume of the mixture was increased with 1 ml of 
DMEM (+1 % glutamine) and then added to the cells. Finally, 100 µl of FCS per well 
was added to the cells 5-6 hours after transfection. Forty-eight hours afterwards, the 
cell supernatant containing the viral particles was collected and 150 µl were directly 
used for transduction. The resulting vectors were titrated on Raji cells. For measles 
virus pseudotyped vectors, 0.15 µg H-plasmid and 0.46 µg F-plasmid were used, for 
VSV-G-pseudotyped vectors, 0.6 µg of pMD.G2 (Didier Trono, Tronolab, Lausanne, 
Switzerland). 
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For all other experiments, vector stocks were produced by transfection using 70 µl 
PEI and 310 µl glucose for a T175 flask. One day before transfection, 1.5 x 107 293T 
cells were seeded and transfected with 28.7 µg of packaging plasmid, 30.2 µg of 
transfer vector plasmid and 5.3 µg each of TPMV-H and F-expression plasmids. The 
measles virus H protein expression plasmid 4 was used in an amount of 2.6µg, the 
measles virus F protein plasmid in an amount of 8 µg. For VSV-G-pseudotyped 
vectors, 10.6 µg pMD.G2 plasmid was used. To the transfection mixture 2.2 ml 
DMEM (+1% glutamine) was added. For concentrating the vector particles, the 
supernatant was collected after 48 hours, filtered (0.45 µm filter) and centrifuged by 
low-speed centrifugation over a sucrose-cushion (20 % wt/vol) (4000 g for 24 hours 
at 4 °C). The supernatant was discarded and the pellet was resuspended in 60 µl 
Opti-MEM (200 µl for VSV-G-pseudotyped vectors).  
For stability assays, vectors were concentrated by ultracentrifugation or ultrafiltration.  
Ultracentrifugation was performed at 28,000 rpm for 3 hours at 4°C over a sucrose-
cushion (20 % wt/vol). For ultrafiltration, the vector-containing cell supernatant was 
applied to Amicon 100-ultra centrifugal filter units (Millipore) and centrifuged at 4000 
g for 90 min at 4°C.   
 
5.2.7. Titration of lentiviral vectors 
Vector titration was done using Raji cells. For the initial screening of all TPMV-F-and 
H-protein combinations, 2.0 x 104 Raji cells were seeded on the day of transduction 
into a single well of a 96-well plate in a total amount of 50 µl. The vector stocks were 
serially diluted in steps of 1:10 in a total volume of 200 µl. Of these dilutions, 150 µl 
were added to the cells together with 4 ng/ml protamine sulfate and incubated for 3 
hours at 37°C. Then, 100 µl fresh medium was added to the cells. After 72 hours, 
GFP-positive cells were determined by FACS analysis and the titer was calculated. 
For titration of large scale productions, 1.0 x 105 cells (Raji) were seeded into a single 
well of a 48 well plate. Serial dilutions were performed in a total volume of 300 µl and 
250 µl were added to the cells together with 4 ng/ml protamine sulfate. After 3 hours, 
0.7 ml fresh medium was added to the cells and FACS analysis was performed 72 
hours after transduction. For titer calculation, dilutions were chosen in which 2 – 20 
% of the cells showed GFP expression. Titers (in transducing units (t.u.)/ml) were 
calculated using the following formular: 
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   Titer [t.u./ml] =  Number of cells at time of transduction   X   GFP positive cells [%] 
                            Volume of vectors                                                    100 
 
5.2.8. Transduction of adherent and suspension cells 
One day before transduction of adherent cell lines, 5.0x104 cells were seeded into a 
single well of a 24 well plate. Before transduction, the medium was removed. 
Depending on vector titer and MOI (multiplicity of infection), vectors were diluted with 
medium in an appropriate ratio in a total volume of 300 µl which was then added to 
the cells together with 4 ng/ml protamine sulfate and incubated for 3 hours at 37°C. 
Then, 700 µl of fresh medium was added.  
For transduction of suspension cells, 1.0x105 cells were seeded on the day of 
transduction into a single well of a 48 well plate in a total amount of 50 µl. As 
described above, vector and medium was mixed in an appropriate ratio depending on 
vector titer and MOI and added to the cells together with 4 ng/ml protamine sulfate 
and incubated for 3 hours at 37°C. Then, 700 µl of fresh medium was added.  
For the transduction of the mixed cell population, 5.0x104 Raji cells together with 
5.0x104 K-562 cells were seeded into a single well of a 48-well plate in a total amount 
of 50 ml and transduced as described above. FACS analysis was performed 72 
hours after transduction. 
 
5.2.9. Transduction of primary human B cells 
For transduction, the isolated B cells were seeded into a single well of a 48 well plate 
(5.0 x 104 cells/well) together with the virus particles in a total volume of 300 µl and 
with 4 ng/ml protamine sulfate. This was followed by centrifugation at 430 g for 30 
min at 32°C. Subsequently, the cells were incubated at 37°C. Next day, 500 µl/well 
medium (as described above) was added to the cells and 72 hours after transduction, 
the fraction of GFP-positive cells was determined by FACS analysis. 
 
5.2.10. Neutralization assay 
To examine whether TPMV-pseudotyped LVs by MV-antibodies, human sera were 
heat-inactivated for 30 min at 56°C and stepwise diluted (1:20) in medium without 
FCS. 100 µl each of these dilutions were incubated for 20 min at 4°C with the 
appropriate amount of vector stock using a MOI of 0.4. Afterwards, the vector-
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containing serum dilutions were incubated for 5 min at 37°C and 2.0x104 Raji cells in 
an amount of 20 µl medium without FCS were added. Three hours later, 100 µl fresh 
medium (+ FCS) was added to the cells and 72 hours after transduction, GFP 
expression was analyzed by FACS.  
 
5.2.11. Cultivation and concentration of the Tupaia paramyxovirus 
TPMV was propagated in TBF cells (Tupaia baby fibroblasts). TBFs were infected 
when they were 80 % confluent with 1 ml frozen virus-containing cell supernatant by 
adding the virus to the medium. After 5-6 days, the supernatants of two T175 flasks 
were combined and ultra-centrifuged at 28,000 rpm for 3 hours at 4°C over a 20% 
sucrose-cushion. The virus-containing pellet was resuspended in 200 µl PBS.  
 
5.2.12. Fluorescent activated cell sorting (FACS) 
FACS analysis was performed on a BD LSRII flow cytometer (Becton Dickinson, 
Heidelberg, Germany). Raji and K-562 cells were washed twice in 500 µl FACS 
washing buffer (phosphate-buffered saline, 1% FCS, 0.1% NaN3) and finally 
resuspended in 100 µl phosphate-buffered saline/1% paraformaldehyde. To detect 
CD20-positive cells, the cells were incubated with a 1:10 dilution of the mouse anti-
human CD20/PE-Cy5 antibody (BD Pharmingen, Heidelberg, Germany) after the first 
washing step. After 20 minutes at 4°C, the antibody solution was removed and the 
cells were washed twice and fixed as described before. For detection of CD19-
positive cells, the mouse anti-human CD19/PE antibody (DakoCytomation, Hamburg, 
Germany) was used. Stimulated B cells were detected by an antibody against the 
activation marker CD69 (mouse anti-human CD69/FITC, DakoCytomation, Hamburg, 
Germany). The data were analyzed with the FCS-Express V3 program. 
 
5.3. Biochemistry 
5.3.1. SDS-Polyacrylamide gelelectrophoresis 
For analysis of protein expression levels and for separation of proteins according to 
their molecular weight, a sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) was applied (Laemmli, 1970). In this method, proteins get denatured 
and negatively charged in the presence of sodium dodecyl sulphate (SDS). Thus, 
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they can be applied to electrophoresis and run towards the positive pole under 
current conduction. Additionally, exposed disulfide bonds are reduced by the 
presence of dithiothreitol (DTT) resulting in prevention of intra- and intermolecular 
interactions by disulfide bond formation.  
For analysis, proteins were resuspended in a defined volume of PBS or RIPA-Lysis 
buffer and 5 volumes of 6 x SDS sample buffer. Samples were denatured by 
incubation for 5 minutes at 95 °C. Afterwards, the protein samples were applied to 10 
% sodium dodecyl sulfate-polyacrylamide electrophoresis gels within a Bio-Rad-Mini 
Protean II chamber filled with SDS-running buffer. As protein ladder, Precision Plus 
Protein Standards Dual Color (Bio-Rad) was used. For separation of proteins inside 
the stacking gel a voltage of 80 V was used, whereas the voltage was raised to 120 
V inside the separating gel until the dye front had left the separating gel. 
 
5.3.2. Western Blot analysis 
This technique allows the transfer of proteins onto a Polyvinylidene fluoride (PVDF) 
membrane. Based on this transfer, proteins can be visualized by immunostaining 
with specific antibodies. In general, proteins are transferred onto membranes after 
SDS-Polyacrylamide gelelectrophoresis, a process also called blotted. In this thesis, 
proteins were blotted using a wet blot. To set up the blot, the membrane was shortly 
incubated in methanol for activation and subsequently soaked in Western Blot 
transfer buffer together with four Whatman filter papers and two Western Blot 
sponges. Blotting was performed at 100 V for 1 hour or at 30 V overnight in transfer 
buffer. Subsequently, the blot was incubated in 10% milk powder/TBS-T for one hour 
(RT) or overnight (4°C) to block unspecific protein binding sites. Specific primary 
antibodies were diluted in 5% milk powder/TBS-T, respectively, and incubated with 
the membranes for 1 hour at room temperature or overnight at 4°C. Then, the 
membrane was washed once with 1 x TBS-T and at least three times with 1 x TBS 
for 10 min followed by an one hour incubation with the secondary horse radish 
peroxidase (HRP)-coupled antibody directed against the first antibody at a dilution of 
1 : 2000. Again, the membrane was washed as mentioned above. Detection of 
specific bands was carried out using the enhanced chemiluminescence system 
(ECLTM) Western Blotting Detection Reagent. Hyperfilm ECL films were exposed to 
the resulting chemiluminescent signal. Different exposure times were chosen, 
depending on the quality of specific antibodies. 
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5.3.3. Preparation of cell lysates 
Cells were grown in 6 wells and washed with 2 ml ice-cold PBS. Subsequently, 200 
µl RIPA-lysis buffer were added and the plate was incubated for 5 min on ice. After 
incubation, the lysate was carefully transferred into a 1.5 ml reaction tube and 
centrifuged at 13,000 rpm for 10 min at 4°C in a table centrifuge to remove the cell 
debris. The resulting supernatant was then transferred into a fresh 1.5 ml reaction 
tube and either used immediately for Bradford assay or stored at -20°C.  
 
5.3.4. Protease inhibitor assays 
To identify the protease involved in TPMV F protein processing different protease 
inhibitors were tested. The inhibitors were diluted as recommended by the 
manufacturer (Roche). Cells were transiently transfected in a 6 well plate as 
described before. Five hours after transfection, the medium was replaced by 2 ml 
fresh medium supplemented with protease inhibitors. Cell lysates were harvested 48 
hours after transfection as described above.  
 
5.3.5. Bradford assay   
For determination of protein concentration of cell lysates the Bradford Dye reagent 
from Bio-Rad was used according to the manufacturer’s instructions. Absorption of 
protein samples was measured in a spectrophotometer at a wavelength of 595 nm. A 
standard curve was determined and protein concentrations were calculated.    
 
 
 Results  
 
 
50 
6. RESULTS 
6.1. Generation and characterization of modified TPMV 
glycoproteins  
The aim of this thesis is to develop and characterize targeted lentiviral vectors (LVs) 
that are pseudotyped with the Tupaia paramyxovirus (TPMV) F and H glycoproteins. 
Recently, it was reported that lentiviral vectors can be pseudotyped with the 
glycoproteins of measles virus (MV) when their cytoplasmic tails are truncated 
(Frecha et al., 2008; Funke et al., 2008a; Funke et al., 2009).  Accordingly, a panel of 
TPMV H and F proteins with truncated cytoplasmic tails was generated and 
biochemically characterized. Since it was previously shown that the TPMV 
attachment protein (H) can be retargeted to cell surface molecules similar as the MV 
H protein (Springfeld et al., 2005), a single-chain antibody (scAb) against CD20 was 
displayed on the ectodomain. To identify TPMV cytoplasmic tail variants that have 
the potential to form functional pseudotyped LVs, surface expression of the H protein 
variants and syncytia assays were performed.  
 
6.1.1. Modification of the TPMV H protein 
The TPMV H protein is a type II membrane protein with a length of 665 amino acids 
and has an unusually long cytoplasmic tail of 94 amino acids. It can be retargeted to 
cell surface molecules by displaying single-chain antibodies on the ectodomain 
(Springfeld et al., 2005). Since the retargeted MV-pseudotyped LVs were established 
with a scAb against the B cell surface marker CD20 displayed on the ectodomain of 
the MV H protein, this molecule was also chosen as a target to establish the TPMV-
pseudotyped vectors. 
To retarget the TPMV H protein to CD20, the open reading frame of the 
corresponding scAb was amplified from the plasmid pCGHαCD20 (Bucheit et al., 
2003) and after cutting with BssII and XbaI, the fragment was cloned into the plasmid 
pCG-TPMV-HXαCEA (Springfeld et al., 2005), thereby exchanging the CEA scAb 
against the CD20 scAb on the carboxyterminus of the H protein, resulting in the 
plasmid pCG-TPMV-HαCD20 (Fig. 11A). 
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Figure 11: Schematic drawing of the TPMV H protein, amino acid sequences of the truncated 
cytoplasmic tails and Western blot analysis of the different H protein variants  
For retargeting, a single chain antibody (scAb) against CD20 was fused to the carboxyterminus of the 
H protein together with a Factor X cleavage site (A). The glycoprotein’s cytoplasmic tail (CT) was 
truncated as indicated (B). All proteins were expressed in 293T cells, fractionated by SDS-10% PAGE, 
and detected with a peptide antiserum against the ectodomain of the H protein (αHecto, C) 
TM: transmembrane domain; UT: untransfected cells 
 
 
Measles virus-pseudotyped LVs can only been generated when cytoplasmic tails of 
the glycoproteins are truncated. For the MV H protein, a deletion of 18 amino acids 
results in highest vector titers. Accordingly, a panel of TPMV H proteins with 
truncated cytoplasmic tails was generated by mutation PCR, where the numbers of 
deleted amino acids were randomly chosen. For the different deletions forward 
primers were used that are complementary until the start codon followed by an 
interruption and continue exactly after the deleting sequence. Additionally, the 
forward primers introduced a BamHI cleavage site. The reverse primer was the same 
for all TPMV H variants and introduced an XbaI cleavage site after the stop codon. 
As initial plasmid pCG-TPMV-HαCD20 was used. The resulting PCR fragments 
contained a BamHI cleavage site at the 5’ end, a XbaI cleavage site at the 3’ and 
were deleted by 20, 40, 50, 60, 70, 80 or 84 amino acids at the aminoterminus (Fig. 
11, B), leaving only 10 aa on the shortest variant (HΔ84αCD20). Subsequently, the 
TPMV HαCD20-coding region in the original plasmid pCG-TPMV-HαCD20 was 
replaced upon BamHI/XbaI digestion by the PCR fragments.  
COOH  scAb αCD20 
918 665 
Factor X cleavage site 
TPMV-HαCD20 
MDYHS//LQSQSGSRDTLDGPPSTLQHYSNPPPYSEEDQGIDGPQRSQPLSTPHQYDRYYGVNIQHTRVYNHLGTIYKGLK   H 
M......LQSQSGSRDTLDGPPSTLQHYSNPPPYSEEDQGIDGPQRSQPLSTPHQYDRYYGVNIQHTRVYNHLGTIYKGLK   HΔ20 
M..........................YSNPPPYSEEDQGIDGPQRSQPLSTPHQYDRYYGVNIQHTRVYNHLGTIYKGLK   HΔ40 
M....................................DQGIDGPQRSQPLSTPHQYDRYYGVNIQHTRVYNHLGTIYKGLK   HΔ50 
M..............................................QPLSTPHQYDRYYGVNIQHTRVYNHLGTIYKGLK   HΔ60 
M........................................................RYYGVNIQHTRVYNHLGTIYKGLK   HΔ70 
M..................................................................RVYNHLGTIYKGLK   HΔ80 
M......................................................................HLGTIYKGLK   HΔ84 
C 
 
TM CT 
B 
A NH2 
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For biochemical analysis of the different TPMV H protein variants, 293T cells were 
transfected with the respective plasmids and after 48 hours cell lysates were 
harvested, applied to SDS-polyacrylamide-gelelectrophoresis and analyzed by 
Western Blot using the Hecto antibody. In repeated experiments, no relevant 
differences in the expression levels of the H protein were observed (representative 
Blot is shown in Fig. 11, C). Fusion of the αCD20 scAb to the carboxyterminus of the 
H protein resulted in a larger molecular mass of approximately 110 kDa compared to 
the unmodified H protein. As expected, H protein size was reduced in the proteins 
with truncated cytoplasmic tail. 
 
6.1.2. Modification of the TPMV F protein  
The TPMV F protein is a 553 amino acid type I membrane protein. It is expressed as 
a F0 precursor protein and, in addition to the removal of the signal peptide, cleaved 
during activation, resulting in the fragments F1 and F2 (Fig. 12, A).  
 
                
 
                  
Figure 12: Scheme of the TPMV F protein and sequences of the truncated cytoplasmic tails and 
Western blot analysis of different F protein variants  
TPMV F is expressed as F0 precursor protein and cleaved during activation, resulting in the fragments 
F1 and F2 (A). For pseudotyping, the cytoplasmic tail (CT) was truncated as indicated (B) or replaced 
by the truncated cytoplasmic tail of Measles virus F protein (F MV3). All proteins were expressed in 
293T cells, fractionated by SDS-10% PAGE, and detected with a peptide antiserum against the 
ectodomain of the F protein (αFecto, C) 
TM: transmembrane domain; SP: signal peptide; FP: fusion peptide, UT: untransfected cells 
SP FP TM CT    
F0 
F2 F1 
553 
COOH 
A 
B 
C 
F         KIWSKLHFLDSYVYSLRNPSHHRSNGHQNHSFSTDISG 
FΔ8       KIWSKLHFLDSYVYSLRNPSHHRSNGHQNH 
FΔ18      KIWSKLHFLDSYVYSLRNPS 
FΔ25      KIWSKLHFLDSYV                
FΔ32      KIWSKL 
FΔ33      KIWSK 
FΔ34      KIWS 
FΔ35      KIW 
F MV3     RGR 
    NH2 
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The production of the plasmid encoding the unmodified TPMV F protein was already 
described (Springfeld et al., 2005). Corresponding to the TPMV H protein, the 
cytoplasmic tail of the F protein was truncated at the carboxyterminus by 8, 18, 25, 
32, 33, 34, and 35 amino acids, leaving only three residues on the shortest variant 
(Fig. 12, B). This was done by PCR using a reverse primer that introduced a stop 
codon and an XbaI cleavage side behind the respective amino acid in the plasmid 
pCG-TPMV-F at the 3’ end of the protein coding sequence. The forward primer 
introduced a BamHI at the 5’ end of the PCR product. Additionally, a protein was 
generated that has the same three-amino acid cytoplasmic tail (arginine - glycine - 
arginine) as the recently described MV protein that was used successfully to 
pseudotype lentiviruses (Funke et al., 2008a). In Western blots, all F protein variants 
were expressed at a similar level and according to their predicted sizes (Fig. 12, C). 
The proteins were detected with a novel antibody generated against a peptide in the 
ectodomain of the F protein (αFecto). Surprisingly, with this antibody an additional 
fragment with a molecular mass of about 45 kDa was detected, suggesting that the F 
protein is cleaved twice in addition to the removal of the signal peptide, resulting in 
the fragments F1a, F1b and F2. However, in the proteins with the shortest 
cytoplasmic tails (F∆34, F∆35 and F MV3), the F1 fragment was barely detectable, 
suggesting that in these proteins the F1a/F1b cleavage was more efficient than in the 
unmodified protein. The F1a/F1b cleavage is further characterized in section 6.2.  
 
6.1.3. Surface expression of the modified TPMV H proteins 
For further investigation of the modified TPMV glycoproteins the level of protein 
expression of the H protein on the cell surface was tested. Since surface expression 
is a critical step in vector formation (Sakalian and Hunter, 1998; Sandrin et al., 2004) 
it is important to investigate if the proteins are processed correctly after their 
synthesis and displayed on the cell surface. The H protein was heavily modified by 
fusing the scAb to the carboxyterminus and truncating the CT and might therefore not 
be properly processed. For this purpose, 293T cells were transfected with the 
respective TPMV H-plasmids and 48 hours after transfection the cells were 
harvested and incubated with the primary antibody Hecto and the FITC-labeled 
secondary antibody goat-α-rabbit-IgG. Surface expression was then analyzed by 
fluorescence-activated cell-sorting (FACS) and the geometric mean levels of 
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fluorescence intensity, representing the average amount of surface-expressed H 
protein, were compared. Surface expression levels were normalized to that obtained 
after expression of the unmodified TPMV H protein (100 %).  
Surface expression of almost all modified protein variants was not relevantly inhibited 
by the αCD20-scAb (80 – 100 %) (Fig. 13), in contrast, for two variants it was slightly 
increased (112.3 % for HΔ40αCD20 and 116.9 % for HΔ84αCD20). Only for the 
variants HΔ70αCD20 and HΔ60αCD20 the expression level is significantly reduced 
(56.2 % and 66.9 %, respectively).  
 
          
Figure 13: Cell surface expression levels of the different TPMV H protein variants 
293T cells were mock-transfected (black line) or transfected with the different TPMV H expression 
plasmids (grey line), respectively. After 48 hours, mock- and H-transfected cells were stained for 
surface expression using the antibody αHecto and the fluorescence-labeled secondary antibody α-
rabbit-FITC and analyzed by FACS. The geometric mean levels of fluorescence intensity, representing 
the average amount of surface-expressed H variants, were normalized to that obtained after 
expression of the unmodified TPMV H protein (100 %, upper left). 
 
For the TPMV F variants, no antibody is available that allows FACS analysis of 
surface expression.  
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6.1.4. Functional analysis of the truncated TPMV protein variants 
Since surface expression of the modified TPMV H proteins is not the only critical 
step, next the functionality of the truncated protein variants was investigated. To test, 
if the TPMV H proteins with shortened cytoplasmic tail were still able to fulfill their 
fusion helper function and if the truncated TPMV F proteins still mediate membrane 
fusion, HT1080 cells that stable express CD20 were co-transfected with the wildtype 
F protein together with all HαCD20 protein variants and vice versa. Are the proteins 
functional, the cells fuse and form syncytia. For transfection control and for a better 
visualization of syncytia formation, a plasmid encoding GFP was transfected together 
with the TPMV-encoding plasmids. Fourty-eight hours after transfection, the cells 
were monitored for the formation of syncytia.  
Unexpectedly, F proteins with a cytoplasmic tail shorter than 5 amino acids (F∆34, 
F∆35 and F MV3) together with HαCD20 did not support fusion at all, whereas all 
proteins with longer CTs supported fusion similar to the wildtype F protein (Fig. 14 A). 
This indicates that at least 5 amino acids of the cytoplasmic tail of the F protein are 
necessary to mediate membrane fusion. These results correlate with the lack of the 
fusion-triggering F1 fragment in these proteins in Western blots (Fig. 12 C). As a 
control, cells were transfected with a GFP-encoding plasmid only and as expected, 
no syncytia formation was observed. 
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Figure 14: Functional analysis of the modified TPMV glycoproteins in syncytia assays 
HT1080-CD20 cells were transfected with plasmids encoding the modified proteins and a plasmid 
encoding eGFP to test their ability to induce syncytia formation. The untruncated TPMV HαCD20 
together with all F protein variants (A) and unmodified TPMV F with all TPMV H variants (B) were 
tested. Fourty-eight hours after transfection, GFP expression was analyzed by fluorescence 
microscopy (100x magnification). Control: cells transfected with GFP-encoding plasmid only; GFP: 
green fluorescent protein; (+) and (–) indicates the size of syncytia formation 
 
 
In contrast to the results with the F proteins, there was no similar cut-off with a 
complete loss of function observed when the truncated H proteins were tested 
together with TPMV F (Fig. 14 B). However, the degree of fusion was slightly 
reduced in proteins with larger truncation at the cytoplasmatic tail when compared to 
the wildtype. As expected, the untruncated TPMV H protein without the scAb (H) 
does not form syncytia because of the lack of a receptor for TPMV on HT1080 cells.  
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6.2. Identification of a novel TPMV fusion protein fragment 
As already mentioned, the TPMV F protein is expressed as a F0 precursor protein 
and cleaved during activation. To characterize the TPMV F protein mutants with 
truncated modified cytoplasmic tail for pseudotyping lentiviral vectors, a novel 
antibody against a peptide in the ectodomain of the F protein was generated. 
Surprisingly, with this antibody a novel fragment with a molecular mass of about 48 
kDa was detected, suggesting that the F protein is cleaved twice in addition to the 
removal of the signal peptide, resulting in the fragments F1a, F1b and F2 (Fig. 12 A, 
C). In this part of the result section, the additional cleavage of the TPMV F protein is 
further described.  
 
6.2.1. Further characterization of the TPMV F protein with the novel antibody 
Fecto 
The TPMV F gene is located between the gene for the M protein and the attachment 
(H) protein, showing the typical paramyxovirus gene order (Fig. 15, A). The 553 
amino acid protein (61 kDa) has three hydrophobic regions, the signal peptide (SP), 
the fusion peptide (FP), and the transmembrane domain (TM) (as predicted by 
TMHMM, http://www.cbs.dtu.dk/services/TMHMM) (Fig. 15, B). In the ectodomain 
there are four possible glycosylation sites, three on the F2 fragment (11 kDa) and 
one on the F1 fragment (50 kDa), which are all glycosylated (Fig. 15, B, triangles) 
(Springfeld et al., 2005). The novel antibody was generated against the stalk region 
of the protein’s ectodomain (αFecto, amino acids 462 to 480) (Fig. 15, B), 
corresponding to the peptide ELEMDKTQKALDRSNKIL (Fig.15, C, written in bold) 
which is located in the heptad repeat region B (HRB) (von Messling et al., 2004). 
Since a novel fragment around 45 kDa can be detected with αFecto, an additional F 
protein cleavage has to occur downstream of the αFecto binding peptide. Alignment of 
this part of the ectodomain and the transmembrane region of selected 
paramyxoviruses reveals a certain degree of sequence conservation with a 
characteristic pattern of hydrophobic amino acids (Fig. 15, C). 
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Figure 15: Genome organization of TPMV and structure and sequence of the F protein 
The map of the TPMV genome shows typical paramyxovirus gene order (A). In the linear drawing of 
the TPMV F protein (B), the black triangles ( ) indicate the glycosylation sites and the arrows the 
cleavage sites of the F0 precursor protein. Cleavage activation results in the fragments F1a, F1b and 
F2. The grey-colored boxes mark the peptide binding side of the antibodies αFecto and αFcyt.The red-
colored boxes indicate the positions of the heptad repeat regions HRA and HRB. Alignment of the 
F1a/F1b junction, the αFecto binding site (in boldface) and the predicted transmembrane domain (in 
boldface and italic) of TPMV, MV, CDV and Nipah virus shows only low similarities (C). Identical 
amino acids are indicated by an asterisk, highly conserved amino acids are indicated by a colon, and 
well conserved amino acids are indicated by a period. The hydrophobic residues of the first and fourth 
(a and d) positions of heptad repeat region B (HRB) are in red color. HRA: heptad repeat region A; 
SP: signal peptide; FP: fusion peptide; TM: transmembrane domain; CT: cytoplasmic tail; MV: 
measles virus; CDV: canine distemper virus 
 
 
 
6.2.2. The novel F1a fragment is transported along the secretory pathway and 
cleaved at the carboxy-terminus 
For further characterization of the novel TPMV F1a fragment, the glycosylation 
pattern was investigated. For this purpose, 293T cells were transfected with a 
plasmid encoding TPMV F and the protein content of the lysate was determined by 
Bradford assay. Subsequently, the lysate was incubated either with the 
deglycosylation enzyme PNGase F or Endoglycosidase H (Endo H), applied to SDS-
polyacrylamide-gelelectrophoresis and analyzed by Western Blot using the novel 
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Fecto antibody and an antibody against the C terminus of the TPMV F protein (αFcyt, 
Fig. 15, B).  
In lysate analyzed by Western Blot using the Fecto antibody the novel fragment F1a 
with a molecular mass of about 45 kDA was detected, but not with an antibody 
against the cytoplasmic tail (Fig. 16, A) (Springfeld et al., 2005). The lysate was 
incubated with PNGase F, a deglycosylation enzyme that catalyzes the complete 
removal of N-linked oligosaccharide chains from glycoproteins. Digestion with 
PNGase F resulted in fragments with smaller molecular weight, confirming that the 
glycosylation residues were removed. The shift of the F0 fragment was larger 
compared to the F1 and F1a fragment, accordingly to the removal of four 
glycosylation residues on the F0 and only one on the F1 and F1a fragment. To 
investigate whether the new F1a fragment is expressed on the cell surface, the lysate 
was incubated with Endo H. This enzyme is used to monitor posttranslational 
modifications in the Golgi apparatus. It removes only high mannose and some hybrid 
oligosaccharides from N-linked glycoproteins which are added before the protein 
passes the medial Golgi region, but it does not remove complex oligosaccharides. 
Proteins, that are resistant to Endo H, are correctly processed through the Golgi, 
containing complex oligosaccharides added in the trans-Golgi and rapidly transported 
to the cell surface. Endo H-sensitive proteins have not been processed beyond the 
medial Golgi region. As expected, the precursor protein F0 was mostly sensitive 
towards Endo H (Fig. 16 A) resulting in a shift of the signal, respectively. The F1 and 
F1a fragment were almost completely resistant towards the enzyme. These data 
demonstrate that the F0 fragment was mainly located intracellular whereas the F1 
and also the F1a fragment were transported to the cell surface. Two additional bands 
around 60 and 70 kDa were detectable in lysate of TPMV F incubated with Endo H. 
Since these signals were also detectable in lysate of untransfected cells together with 
Endo H, they were probably due to unspecific binding of the αFcyt antibody to the 
enzyme. 
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Figure 16: Deglycosylation of TPMV F variants and Western Blot analysis using αFecto and αFcyt 
The TPMV F protein variants were expressed in 293T cells, the lysate incubated with Endo H or 
PNGase F and fractioned by SDS-10% PAGE followed by detection with αFecto and αFcyt.  
Deglycosylation with PNGase F resulted in a shift of F0, F1 and F1a fragment whereas the F1a 
fragment is resistant to Endo H and could not be detected with αFcyt (A). After PNGase F incubation of 
F variants truncated at their cytoplasmic tails, same deglycosylation pattern of F1a was detected as for 
the unmodified F protein (B).The positions of F0, F1 and F1a are indicated on the left. ut: 
untransfected cells 
 
 
Next, it was investigated, whether the F1a fragment was truncated at the N- or C-
terminus with regard to the F1 fragment. Two selected proteins with truncated 
cytoplasmic tail (FΔ18, FΔ33) were compared to the native TPMV F protein. 293T 
cells were transfected with the respective expression plasmids and the protein 
content of the lysate was determined by Bradford assay. Afterwards, the lysate was 
digested with PNGase F, applied to SDS-polyacrylamide-gelelectrophoresis and 
analyzed by Western Blot using the novel Fecto antibody.  
The F0 and the F1 fragment of the truncated proteins migrated faster according to 
their molecular weight, while the F1a fragment stayed at the same height (Fig. 16, B) 
compared to the unmodified TPMV F protein. This observation demonstrates that the 
F1 fragments were cleaved at the carboxy-terminus, since the molecular weight of 
the F1a fragment was not affected by truncation of the cytoplasmic tail. Hence, the 
cleavage site was estimated to be located closely proximal to the transmembrane 
domain of the protein (amino acids 493 to 515, Fig. 15, C). Since αFecto is directed 
against amino acids 462 to 480, cleavage has to occur downstream of these amino 
acids. It is noteworthy, that a strong F1 signal is detectable in all lysates, 
demonstrating that the second cleavage occurred only in a fraction of the F protein. 
To demonstrate that the second cleavage occurs also in cells naturally infected by 
the Tupaia paramyxovirus, Tupaia baby fibroblasts (TBFs) were transfected with 
expression plasmids for TPMV F, FΔ18 and FΔ33. The lysate was harvested 48 
hours after transfection and protein content determined by Bradford assay. 
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Subsequently, the lysate was applied to SDS-polyacrylamide-gelelectrophoresis and 
Western Blot analysis was performed using Fecto antibody.   
 
 
 
Figure 17: F0, F1a and F1a fragment detection of TPMV F variants expressed in TBF cells 
TBF cells were transfected with TPMV F protein variants and the proteins separated by SDS-10% 
PAGE followed by Western Blot analysis using αFecto. F0, F1 and F1a were detected after expression 
in TBF cells. The positions of F0, F1 and F1a are indicated on the left. ut: untransfected cells 
 
 
All three TPMV F protein fragments (F0, F1, F1a) were detected in cell lysate of 
Tupaia baby fibroblasts after transient transfection with different TPMV F expression 
plasmids (Fig. 17), confirming, that the second F1a/F1b cleavage occurs also in cells 
naturally infected by TPMV. Since TBFs are primary cells and difficult to transfect, all 
further experiments were performed in 293T cells if not indicated different.  
 
 
6.2.3. The TPMV F protein ectodomain is shed into the supernatant of cells  
Next, it was tested whether the F1a fragment was shed into the supernatant of cells 
expressing TPMV F and the modified variants FΔ18 and FΔ33. For this purpose, 
293T cells were transiently transfected with plasmids expressing TPMV F, FΔ18 and 
FΔ33. Fourty-eight hours after transfection, the supernatant of the cells and the 
lysate was harvested. Protein content of the lysate was determined by Bradford 
assay and applied to SDS-polyacrylamide-gelelectrophoresis. Of the supernatant, the 
highest possible volume was applied with subsequent Western Blot analysis using 
Fecto antibody.  
Indeed, the F1a fragment was detected in all supernatants of 293T cells transfected 
with the different plasmids expressing TPMV F protein variants (Fig. 18) and almost 
no amounts of F0 and F1, suggesting, that F1a was secreted and released in the 
supernatant of the cells. Since it was predicted that the membrane anchor is cleaved 
of, the presence of the F1a fragment was expected.  
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Figure 18: TPMV F1a fragment is shed into the supernatant of cells  
Transfection of 293T cells with TPMV F protein variants. The lysate and supernatant were harvested 
and proteins were separated by SDS-10% PAGE followed by Western Blot analysis using αFecto. The 
positions of F0, F1 and F1a are indicated on the left. ut: untransfected cells; Lys: lysate; SU: 
supernatant; inf. Infected TBF cells 
 
 
6.2.4. The TPMV F1a fragment is present in TPMV virions 
Next, it was investigated if the F1a fragment is also present in TPMV virions. 
Although the F1a fragment has lost its membrane anchor, it could possibly be 
present in F protein trimeric complexes as described previously for measles virus 
(von Messling et al., 2004). For this purpose, TBFs were infected with TPMV and 
after 5-6 days, the supernatant (SU) and lysate (Lys) of infected and non-infected 
cells were harvested and analyzed as described before. To exclude detection of F0, 
F1 and F1a in the supernatant due to cell lysis after syncytia formation or shedding, 
the TPMV-virion-containing supernatant was concentrated and purified by ultra 
centrifugation (UC) over a 20 % sucrose cushion. Only 2.5 µg of total protein content 
of concentrated virions was analyzed compared to lysate, whereat a total protein 
concentration of 10 µg was applied.    
Indeed, the F1a fragment was clearly detectable in high amounts in purified TPMV 
virions (Fig. 19). Surprisingly, an additional fragment around 47 kDa was detected in 
virions, which was not present in lysate of infected TBF cells, suggesting that F 
protein processing is even more complex. As expected, no F0 fragment was 
detectable in TPMV virions.  
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Figure 19: The F1a fragment is present in TPMV virions 
Tupaia baby fibroblasts (TBF cells) were infected with TPMV and lysate and supernatant were 
harvested. TPMV-virion-containing supernatant was concentrated and purified by ultra centrifugation 
(UC) over a 20 % sucrose cushion. Proteins were separated by SDS-10% PAGE followed by Western 
Blot analysis using αFecto. The positions of F0, F1 and F1a are indicated on the left. Lysinf: lysate of 
infected TBFs; SUinf;UC: concentrated supernatant of infected TBFs; Lysnon-inf: lysate of non-infected 
TBFs 
 
 
 
6.3. Characterization of the newly identified cleavage site 
Having demonstrated that the novel F1a fragment is not only secreted but cleaved at 
the carboxy-terminus, now the cleavage site between the F1a and F1b-fragment was 
characterized.  
 
6.3.1. Mapping of the F1a-F1b cleavage site 
To determine the cleavage site between the F1a and F1b-fragment, eleven c-
terminally truncated proteins were generated with a Flag-tag added at positions 483, 
491, 492, 495, 498, 501, 505, 507, 510, 513 and 516 (Fig. 20, modified from (von 
Messling et al., 2004)) (Fig. 21, A)  and detected with an αFlag-antibody and the 
αFecto-antibody. It was assumed that the F1a-F1b cleavage may result in loss of 
protein detection, as the αFlag-antibody does not recognize the cleaved protein 
anymore.   
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Figure 20: Schematic drawing of truncated Flag-tagged TPMV F variants 
The TPMV F protein was truncated at indicated amino acid positions and a Flag-tag (white box) was 
fused at the carboxy-terminus, resulting in shorter F1a and F1b fragments compared to the native F 
protein (left).The arrow indicates the expected position of F1a/F1b cleavage. The line connecting F1a 
and F2 fragments symbolizes the disulfide bond. Only four representative Flag variants are shown 
here, F438, F495, F505 and F516.    
 
The different truncated TPMV F-Flag-variants were generated by PCR using primers 
that introduced a Flag-tag at defined amino acid positions, followed by a stop codon.  
Afterwards, 293T cells were transfected with the respective expression plasmids and 
48 hours later, the lysate was harvested and protein content determined by Bradford 
assay. The lysate was then applied to SDS-polyacrylamide-gelelectrophoresis and 
analyzed by Western Blot using the antibodies αFlag and αFecto.  
All F0 fragments were detected using αFecto (Fig. 21, B). However, when the same 
cell lysates were tested in Western Blots with αFlag antibody, TPMV F Flag variants 
longer than 498 amino acids were not detected anymore, suggesting that cleavage of 
F1a/F1B occurred between amino acid position 498 and 501. Surprisingly, there was 
no F1 fragment detectable with αFlag-antibody. Regarding Western Blot analysis with 
αFecto, there was the F0 fragment and a strong signal around 40 kDa, suggesting that 
this was shortened F1 together with F1a. In FFlag variants longer than 498 amino 
acids, the F1 together with F1a signal was strongly decreased. Currently, these 
observations cannot be explained and further investigations are necessary. 
Nevertheless, cleavage site of F1a/F1b was mapped between amino acids 498 and 
501. To map the cleavage site in detail, two further protein variants were generated 
with a flag-tag after amino acid position 499 and 500 and analyzed by Western Blot 
as described before (Fig. 21, C). The variant TPMV F500 was not detected anymore 
by αFlag-antibody, demonstrating that cleavage occurred exactly between amino 
acid 499 and 500. Surprisingly, this position was located in the predicted 
transmembrane domain. Again, no F1 fragments were visible using αFlag antibody. 
In contrast, F1 was detected when the Flag-tag was added after amino acid position 
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533, which is located in the cytoplasmic tail, or at the C-terminal end of the protein 
(amino acid position 553). However, some unexpected results were obtained that 
cannot be explained and might be due to the heavy modifications of the protein.    
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Figure 21: Mapping of F1a/F1b cleavage site by Western Blot analysis of TPMV F Flag-variants 
Scheme of TPMV F transmembrane region (A) and mapping of the F1a/F1b cleavage site (B and C). 
(A) The TPMV F protein was truncated at the indicated amino acid (aa) positions (number and arrow) 
and a Flag-tag was added at the truncation site. The binding peptide of the antibody αFecto is in bold, 
the predicted transmenbrane domain in bold and italics. (B) Western Blot analysis of truncated Flag-
tagged F protein variants. 293T cells were transfected with TPMV F Flag-tagged variants and the 
lysate was harvested. Proteins were separated by SDS-10% PAGE followed by Western Blot analysis 
using the antibodies αFecto and αFlag. (C) Detailed mapping of the cleavage site. A Flag-tag was 
added at single aa positions between aa 498, 501 and aa 533, 553 of TPMV F. Western Blot analysis 
was performed as described before. The positions of F0, F1 and F1a are indicated on the left. ut: 
untransfected cells 
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6.3.2. Mutation of the F1a-F1b cleavage site 
After identification of the exact amino acid positions of the F1a/F1b cleavage site, it 
was investigated whether cleavage was inhibited by mutation of the amino acids, 
respectively. For this purpose, two different cleavage mutants were generated by 
mutagenesis PCR replacing the three amino acids at position 498-500 (FAla1) or at 
position 499-501 (FAla2) by alanin (Fig. 22, A). 293T cells were transfected with the 
respective expression plasmids and 48 hours later, the lysate was harvested and 
protein content determined by Bradford assay. The lysate was then applied to SDS-
polyacrylamide-gelelectrophoresis and analyzed by Western Blot using αFecto-
antibody. 
 
Figure 22: Mutation of the identified F1a-F1b cleavage site does not prevent F1a-F1b cleavage 
Amino acids surrounding the new identified F1a-F1b cleavage site were replaced by alanins resulting 
in the TPMV F mutants FAla1 and FAla2 (A). The mutated amino acids are in red, the binding peptide of 
the antibody αFecto is in bold, the predicted transmenbrane domain in bold and italics. The identified 
cleavage site between valine and phenylalanine is indicated by an arrow. For Western Blot analysis of 
the F mutants (B), 293T cells were transfected with the respective expression plasmids and the lysate 
was harvested. Proteins were separated by SDS-10% PAGE followed by Western Blot analysis using 
the antibody αFecto. The positions of F0, F1 and F1a are indicated on the left. ut: untransfected cells 
 
 
In both F protein mutants, FAla1 and FAla2, the fragments F0, F1 and F1a were 
detected (Fig. 22, B). Compared to the unmodified TPMV protein, there was no 
difference in molecular size of the fragments. These data demonstrate that the F1/F2 
and the F1a/F1b cleavage still occurred, assuming that the mutated amino acids are 
not necessary for F protein cleavage. 
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6.4. Characterization of the cleavage protease 
After mapping the F1a/F1b cleavage site, next step is to characterize the cleavage 
protease. As mentioned before, the F protein is cleaved twice during activation. 
Although the first cleavage (F1/F2) is already described (Springfeld et al., 2005), the 
responsible protease is not yet identified. To get a first overview about the involved 
protease the commercially available protease inhibitor cocktail ‘Complete’ (Roche) 
was tested. One tablet of ‘Complete’ was dissolved in DMEM medium according to 
the manufactures instructions. 293T cells were transfected with pCG-TPMV-F 
expression plasmid and five hours after transfection, the medium was changed 
against medium supplemented with stepwise diluted concentrations of ‘Complete’. 
After 48 hours, the lysate was harvested and protein content determined by Bradford 
assay. The lysate was then applied to SDS-polyacrylamide-gelelectrophoresis and 
analyzed by Western Blot using the αFecto-antibody. 
In the presence of high concentrated protease inhibitor, F0 was detected in very low 
amount, but no F1 and F1a fragment (Fig. 23). In lysates of transfected cells 
incubated with lower ‘Complete’ concentrations small amounts of F1 and F1a were 
presented in addition to the F0 fragment. 
 
            
 
Figure 23: Protease inhibitor prevents F1-F2 and F1a-F1b cleavage 
293T cells were transfected with TPMV F and five hours after transfection the medium was replaced 
by medium supplemented with ‘Roche Complete’ protease inhibitor cocktail in different concentrations. 
48 hours later, the lysate was harvested and proteins were separated by SDS-10% PAGE followed by 
Western Blot analysis using the antibody αFecto. The positions of F0, F1 and F1a are indicated on the 
left. ut: untransfected cells 
 
 
In conclusion, it has been shown that the amount of F1 and F1a increased with lower 
concentrations of ‘Complete’, demonstrating that both cleavages, F1/F2 and 
F1a/F1b, can be inhibited by protease inhibitor added to the medium. Since the exact 
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composition of this inhibitor is confidential, no conclusions about the protease can be 
drawn and further experiments have to be performed.  
 
6.4.1. Screening of different protease inhibitors 
Since it was shown that cleavage of the TPMV protein was prevented by incubation 
with the protease inhibitor cocktail ‘Complete’, the question raised if it is possible to 
identify the cleavage protease by analyzing different protease inhibitors separately.  
For this reason, 293T cells were transfected with TPMV F expression plasmid and 
treated with ten different protease inhibitors as described before. The inhibitors and 
their specificities are summarized in table 1. They were added to the cells in 
concentrations suggested by the manufacturer (Roche, Mannheim).  
 
Table 1: Protease inhibitors and their specificities 
Inhibitor Specificity of Inhibitor 
Antipain-
dihydrochloride 
papain, trypsin is inhibited to a small extent 
Bestatin 
amino peptidase, including aminopeptidase B, leucine 
aminopeptidase, tripeptide aminopeptidase 
Chymostatin α-, β-, γ-, δ-chymotrypsin 
E-64 cysteine proteases 
Leupeptin 
serine and cysteine proteases such as plasmin, trypsin, 
papain, cathepsin B 
Pepstatin 
aspartate proteases like pepsin, renin, cathepsin D, 
chymosin 
Phosphoramidon 
metallo endopeptidases, specifically thermolysine, 
collagenase, metallo endoproteinases 
Pefabloc SC 
serine proteases, e.g. trypsin, chymotrypsin, plasmin, 
thrombin 
EDTA-Na2 metalloproteases 
Aprotinin serine proteases 
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After incubation of the cells for 48 hours with the inhibitors, the lysate was harvested 
and protein content determined by Bradford assay. Afterwards, the lysate was 
applied to SDS-polyacrylamide-gelelectrophoresis and analyzed by Western Blot 
using the αFecto-antibody. 
No cleavage inhibition was achieved with the inhibitors phosphoramidon, EDTA-Na2, 
bestatin, pepstatin and aprotinin, the F1 and the F1a fragment were still detectable in 
high amounts and in addition to the F0 fragment (Fig. 24). In contrast, reduced 
amounts of F1 and F1a were observed when transfected cells were incubated with 
the inhibitors antipain, E-64 and leupeptin and possibly chymostatin. Incubation with 
Pefabloc SC resulted in cell death, thus, no analysis of the effect of this inhibitor on 
protease cleavage was possible.  
 
 
 
 
Figure 24: Screening of ten different protease inhibitors 
293T cells were transfected with TPMV F and five hours after transfection the medium was replaced 
by medium supplemented with the respective protease inhibitors in different concentrations suggested 
by the manufacturer. 48 hours later, the lysate was harvested and proteins were separated by SDS-
10% PAGE followed by Western Blot analysis using the antibody αFecto. The positions of F0, F1 and 
F1a are indicated on the left.  
 
 
Having demonstrated the effects of different protease inhibitors in this first screening, 
now the potentially effective inhibitors chymostatin, antipain, E-64 and leupeptin were 
selected and tested in several concentrations, starting with lowest concentration 
suggested by the manufacturer. Lysate samples were prepared as described before 
followed by Western Blot analysis. 
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In the presence of leupeptin, no cleavage occurred, neither for F1/F2 nor F1a/F1b, 
even with the lowest concentration of 1 µg/ml only the F0 fragment was detectable 
(Fig. 25, A). Antipain inhibited protease cleavage with increasing concentrations (Fig. 
25, B). With higher amounts of inhibitor higher amounts of the F0 fragment were 
detected. The F1 fragment is less, but independently of the inhibitor concentration 
expressed, whereat there was almost no F1a expressed after incubation with 200 
and 400 µg/ml. A similar effect was observed for E-64 (Fig. 25, D). Incubation with 
chymostatin with concentrations of 25 and 50 µg/ml resulted in detection of F0, F1 
and F1a fragments (Fig. 25, C) demonstrating that cleavage is not inhibited.  
 
 
 
Figure 25: F protein cleavage is inhibited by leupeptin, antipain and E-64 
To further characterize the promising protease inhibitors leupeptin (A), antipain (B), chymostatin (C) 
and E-64 (D), 293T cells were transfected with TPMV F and five hours after transfection the medium 
was replaced by medium supplemented with stepwise diluted protease inhibitor, respectively. 48 hours 
later, the lysate was harvested and proteins were separated by SDS-10% PAGE followed by Western 
Blot analysis using the antibody αFecto. The positions of F0, F1 and F1a are indicated on the left.  
 
 
The inhibitors and the respective protease families are summarized in Table 2. Taken 
together, all effective substances (Leupeptin, Antipain, E-64) inhibited the family of 
cysteine proteases. These data suggest that a cysteine protease might be involved in 
F protein cleavage and activation.  
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Table 2: Protease families and their inhibitors  
 Aspartic Cysteine Metallo Serine Threonine 
Inhibition 
of  TPMV F 
cleavage 
Antipain  x  x  + 
Bestatin   x   - 
Chymostatin  x  x  - 
E-64  x    + 
Leupeptin  x  x x + 
Pepstatin x     - 
Phosphoramidon   x   - 
Pefabloc SC    x  - 
EDTA-Na2   x   - 
Aprotinin    x  - 
 
 
6.4.2. F protein cleavage is necessary for cell fusion 
To answer the question if F1/F2 and F1a/F1b cleavage is necessary for cell fusion 
the effect of the three identified protease inhibitors leupeptin, antipain and E-64 were 
examined in fusion assays. TBF cells were transiently transfected with TPMV-H- and 
–F-expression plasmids. Five hours after transfection the medium was replaced by 
medium supplemented with the protease inhibitors at different concentrations, 
respectively, and as control, medium without inhibitor was added.  Fourty-eight hours 
later, the cells were observed under the microscope and the lysate was harvested. 
Afterwards, the protein content was determined by Bradford assay and the lysate 
applied to SDS-polyacrylamide-gelelectrophoresis and analyzed by Western Blot.  
As expected, TBF cells transfected with pCG-TPMV-H and pCG-TPMV-F fused and 
form large syncytia after incubation with non-supplemented medium (Fig. 26). 
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Figure 26: TBF cells form large syncytia after transfection with TPMV H and F 
TBF cells were transfected with expression plasmids for TPMV H and F. Fourty-eight hours after, cells 
were analyzed by microscopy using 10x magnification and representative pictures were taken. Left: ut, 
untransfected cells; right: cells transfected with TPMV F and H.  
 
 
In TPMV-H and –F-transfected TBFs incubated with antipain-supplemented medium 
(100 µg/ml and 400 µg/ml) fusion of cells was completely inhibited (Fig. 27). For E-64 
and Leupeptin, a complete inhibition of cell fusion was only observed when cells 
were incubated with higher inhibitor concentrations [80 µg/ml].  
 
 
 
Figure 27: Protease inhibitors prevent syncytia formation of TPMV F/H-transfected TBF cells 
TBF cells were transfected with expression plasmids for TPMV H and F. Five hours after transfection, 
the medium was replaced by medium supplemented with the protease inhibitors antipain, E-64 or 
leupeptin in two different concentrations. 48 hours later, cells were analyzed by microscopy using 10x 
magnification and representative pictures were taken. 
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6.5. Pseudotyping of lentiviral vectors with the modified TPMV 
proteins 
Characterization of the modified TPMV glycoproteins showed that all variants were 
expressed after transient transfection. Additionally, modified TPMV H proteins that 
are expressed on the cell surface and have fusion helper function were identified, as 
well as F proteins with truncated cytoplasmic tails, that still support fusion of the cell 
membrane. The next step for generating retargeted lentiviral vectors was to 
pseudotype them with the modified TPMV glycoproteins.  
 
6.5.1. Generation of TPMV-pseudotyped vectors  
In a first screening, the untruncated TPMV HαCD20 protein was tested together with 
all F protein variants for the ability to pseudotype lentiviral vectors. For the 
production, 293 T cells served as packging cells and were transiently transfected in a 
T75 flask with the packaging plasmid pCMVΔR8.9, the green fluorescent protein 
(GFP) encoding transfer vector plasmid pSEW, the TPMV HαCD20 plasmid and one 
of the TPMV F variant-encoding plasmids, respectively. The TPMV-plasmids were 
used in equal amounts. As positive control, VSV-G-pseudotyped vectors were 
generated by transfection of the VSV-G encoding plasmid pMD.G2 along with the 
packaging and transfer plasmids. Additionally, vector particles that are pseudotyped 
with MVNSe HΔ18αCD20 and FΔ30 (MV vaccine strain Edmonston B) or MVWT HΔ18 
and FΔ30 (MV wildtype strain) (Funke et al., 2008a) were produced. Fourty-eight 
hours after transfection, the supernatants of vector-producing 293T cells were 
harvested, concentrated by low-speed centrifugation and used for transduction of the 
CD20-positive cell line Raji (Human Burkitt's lymphoma cell line). After 72 hours, the 
transduced cells were analyzed by FACS (fluorescent activated cell sorting) and the 
titers were calculated. 
Efficiency of transfection was analyzed by fluorescence microscopy. The packaging 
cells showed high GFP expression due to the pSEW plasmid (Fig. 28). For both MV 
and TPMV vector producing cells, syncytia formation was observed that was possibly 
due to the high transfection levels and αCD20-scAb interactions. In MV-vector 
producing cells, syncytia formation was increased, probably because of incomplete 
mutation of the MV H contact residues to the MV receptors.  
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Figure 28: GFP expression of packaging cells after plasmid transfection for LV generation 
293T packaging cells were co-transfected with lentiviral expression plasmids and plasmids encoding 
TPMV HαCD20 and F (LV-TPMVαCD20) or MVNSe HΔ18αCD20 and FΔ30 (LV-MVNSeαCD20), 
respectively. Fourty-eight hours after transfection, GFP expression was analyzed by fluorescence 
microscopy (100x magnification). Representative pictures are shown. Scale bar: 200 µm 
 
 
Seventy-two hours after transduction of Raji cells, highest titers of the TPMV-
pseudotypes were achieved with HαCD20 together with the unmodified F, FΔ18 and 
FΔ32 (9x105 – 3x106 t.u./ml) (Fig. 29). These values are almost in the same range as 
the MVNSe-control (3.5x106 t.u./ml). Higher titers were only reached with MVWT-
pseudotypes (5x107 t.u./ml) and vectors pseudotyped with VSV-G (4x1010 t.u./ml).  
 
 
 
Figure 29: Initial screening titers of TPMV HαCD20 and F protein variants to pseudotype LVs 
293T cells were co-transfected with lentiviral expression plasmids and plasmids encoding TPMV 
HαCD20 and different truncated F variants, respectively. After 48 hours, vector-containing supernatant 
was harvested and concentrated by low-speed centrifugation for 24 hours at 4°C. The pellet was then 
used for transduction of Raji cells. Seventy-hours later, GFP expression was analyzed by FACS and 
titers [t.u./ml, titration units/ml] were determined. The arrows indicate titers below the detection limit. 
MVNSe: glycoproteins of measles virus vaccine strain Edmonston B, HΔ18αCD20 and FΔ30; MVWT: 
glycoproteins of measles virus wild type strain, HΔ18 and FΔ30; VSV-G: glycoprotein of vesicular 
stomatitis virus; GFP: green fluorescent protein; LVs: lentiviral vectors 
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Surprisingly, TPMV HαCD20 together with untruncated F allowed efficient 
pseudotype formation (3x106 t.u.ml). This is in contrast to the MV-pseudotyped 
vectors, where only truncated MV glycoproteins could be incorporated (Funke et al., 
2008a). In accordance with the results obtained in syncytia assays, F proteins with a 
cytoplasmic tail shorter than 5 amino acids are not able to mediate gene transfer, as 
well as the TPMV H protein without the αCD20-scAb.   
In further experiments, MVNSe truncated and retargeted glycoproteins (HΔ18αCD20 
and FΔ30) are used as a control and will be referred to as LV-MVαCD20.  
 
 
6.5.2. Screening of all TPMV H and F protein variants 
Next, all TPMV H and F protein variants were screened in all combinations for their 
ability to mediate gene transfer into CD20-positive cells. Since it is associated with 
high effort to test all combinations in T75 flasks, this screening was performed in a 6 
well format.    
Vectors were produced by transfection of 293T cells with lentiviral expression 
plasmids and plasmids encoding the TPMV glycoproteins in equal amounts as 
described above, but with corresponding less plasmid DNA and in a 6 well plate. Two 
days post transfection, the supernatant of the packaging cells was directly used for 
transduction of CD20-positive Raji cells in a 96 well plate. After 48-72 hours, 
transduced cells showed GFP expression and were analyzed by FACS. Based on 
the percentage of GFP-expressing cells the titer (transducing units (t.u.)/ml) was 
calculated. 
Titers obtained by screening all F and H protein combinations are shown in Table 3.  
 
 
 
 
 
 
 
 
 
 
 Results  
 
 
76 
Table 3: Screening titers of TPMV H and F combinations for LV-pseudotyping 
TPMVa 
[t.u./ml] HαCD20  HΔ20αCD20  HΔ40αCD20  HΔ50αCD20  HΔ60αCD20  HΔ70αCD20  HΔ80αCD20  HΔ84αCD20  TPMV-H 
F  4.0E+04 2.9E+03 4.9E+03 4.6E+03 2.3E+04 6.3E+04 5.2E+04 1.4E+04 < 1.3E+03 
FΔ8 8.9E+03 < 1.3E+03 < 1.3E+03 1.8E+04 1.9E+04 4.6E+03 5.4E+04 1.8E+04 < 1.3E+03 
FΔ18 4.2E+04 2.9E+03 1.3E+04 1.8E+04 3.4E+04 1.1E+04 8.9E+04 4.9E+04 < 1.3E+03 
FΔ25 6.1E+04 7.4E+03 6.0E+04 1.9E+03 2.1E+04 2.6E+04 8.4E+04 5.9E+04 < 1.3E+03 
FΔ32 3.1E+04 5.4E+03 8.4E+04 1.7E+03 6.9E+04 2.9E+04 1.3E+05 9.9E+04 < 1.3E+03 
FΔ33 2.0E+04 < 1.3E+03 1.5E+04 3.4E+03 1.3E+04 3.5E+03 2.3E+04 6.2E+03 < 1.3E+03 
FΔ34 < 1.3E+03 < 1.3E+03 < 1.3E+03 < 1.3E+03 < 1.3E+03 < 1.3E+03 < 1.3E+03 < 1.3E+03 < 1.3E+03 
FΔ35 < 1.3E+03 4.3E+03 < 1.3E+03 < 1.3E+03 < 1.3E+03 < 1.3E+03 < 1.3E+03 < 1.3E+03 < 1.3E+03 
F MV3 2.6E+03 < 1.3E+03 3.4E+03 8.1E+03 1.7E+03 < 1.3E+03 < 1.3E+03 < 1.3E+03 < 1.3E+03 
          
detection limitb 1.3E+03              
< 1.3E+03           
1.3E+03 - 1.00E+04            
1.0E+04 – 1.0E+05         
> 1.0E+05           
 
 
Highest titers (105 t.u./ml) were reached with the truncated F variant FΔ32, where 
only six amino acids of the cytoplasmic tail were left, together with HΔ80αCD20 that 
has a cytoplasmic tail length of 14 aa (Table 3). High titers were also obtained with 
the combinations HΔ80αCD20 / FΔ18 and HΔ84αCD20 / FΔ32 (9.8 x 104 and 9.9 x 
104 t.u./ml). Concentration of pseudotyped vectors produced in large scale (T75 or 
T175 flask) by low speed centrifugation increased titers up to about 106 t.u./ml. 
Altogether, there was a trend to higher titers when glycoproteins with shorter 
cytoplasmic tails were used. However, F proteins with cytoplasmic tails shorter than 
five amino acids did not lead to infectious vectors. Considering the loss of 
fusogenicity of these proteins in fusion assays, this result was expected and already 
observed in a first screening (Fig. 18). In this screening it was also shown that in 
contrast to MV, it was possible to pseudotype lentiviral vectors with unmodified 
TPMV H and F proteins although titers were low.  Untargeted TPMV H protein was 
used as a negative control, truncated MV glycoproteins (Funke et al., 2008a) were 
used as a positive control and led on average to vector titers in the range of 2-3 x 104 
t.u./ml (data not shown). VSV-G-pseudotyped vectors reached titers much higher 
than 106 t.u./ml that were above the detection limit in this experiment. The optimal 
TPMV F and H combination identified in this screening was used for all further 
experiments (HΔ80αCD20 together with FΔ32) and will be referred to as LV-
TPMVαCD20.  
 
a screening titers in transducing units/ml [t.u./ml];   
  screening was performed in duplicate 
b detection limit: detection of > 1 % GFP expression in FACS analysis 
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6.5.3. Determination of the optimal H to F ratio 
In natural occurring MV infections, it was shown, that more F mRNA than H mRNA is 
produced (Cattaneo et al., 1987a; Plumet, Duprex, and Gerlier, 2005). Following this 
observation, the H to F ratio of MV-pseudotyped vectors was optimized, which 
resulted in a more than ten-fold increase in titer. The optimal ratio of H to F identified 
for MV was 1 : 7 (Funke et al., 2008a). Since there is a gradient of mRNA in all 
paramyxoviruses, it was tried to enhance titers of TPMV-pseudotyped by optimization 
the TPMV HΔ80αCD20 to FΔ32 plasmid ratio.  
For this purpose, vectors were produced by co-transfection of 293T cells in T75 
flasks with the lentiviral expression plasmids and different ratios of pCG-TPMV-
HΔ80αCD20 and pCG-TPMV-FΔ32, respectively. After 48 hours, the cell 
supernatants were harvested and concentrated for 24 hours by low-speed 
centrifugation. The concentrated particles were then used for transduction of Raji 
cells. Seventy-two hours later, GFP expression was analyzed by FACS and titers 
were calculated. The titers were normalized to that obtained after transfection of 
equal amounts of pCG-TPMV-HΔ80αCD20 and pCG-TPMV-FΔ32.  
 
 
                    
Figure 30: Identification of optimal H : F ratio for pseudotyping lentiviral vectors 
During vector production, the plasmid ratio of HΔ84αCD20 to FΔ32 was altered as indicated. Vectors 
were titrated on Raji cells and titers determined by FACS analysis. Titers were normalized to that 
obtained after transfection with equal amounts of TPMV HΔ84αCD20 and FΔ32 expression plasmids 
(100%). This figure shows the average of 3 independently experiments.  
 
 
In contrast to MV-pseudotypes, there was no significant enhancement of titers by 
altering the ratio of HΔ80αCD20 and FΔ32 plasmids during vector particle production 
(Fig. 30). The data show the average of 3 independent experiments. Titers obtained 
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with equal amounts of H and F plasmids were slightly higher than that obtained with 
other H : F ratios. Using lesser amounts of H or F plasmids, respectively, resulted in 
a decrease of titers. Compared to MV-pseudotypes, where a ratio of 1 : 7 is optimal 
for production, in this case, in a ratio of 1 : 7 and vice versa the titers were decreased 
to less than 15 %. Further experiments were performed in a HΔ80αCD20 and FΔ32 
plasmid ratio of 1 :1.  
 
6.5.4. Confirmation of incorporation of the modified TPMV proteins into LVs  
Having demonstrated that lentiviral vectors pseudotyped with truncated TPMV 
glycoproteins mediated efficient gene transfer, now the incorporation level of the 
gylcoproteins was investigated.  
For this purpose, TPMVαCD20 vectors were generated as described before, 
concentrated and purified by low speed centrifugation over a 20 % sucrose cushion 
for 24 h at 4°C. The vectors were resuspended in PBS, inactivated for 5 minutes at 
95°C and their protein content determined by Bradford assay. As a control, 293T 
cells were transfected with HΔ80αCD20- or FΔ32-plasmids. After 48 hours, the cells 
were lysed and the protein content determined. The purified particles and the cell 
lysates were applied to SDS-polyacrylamide-gelelectrophoresis and analyzed by 
Western Blot.  
Both glycoproteins were detectable in the particles and migrated according to their 
molecular size albeit HΔ80αCD20 was barely detected (Fig. 31, lane 1). A stronger 
signal was observed for FΔ32 and the fragments F0 and F1 were detectable whereat 
F1a seemed not to be present. This observation was very different from the F protein 
fragments present in TPMV virions (section 6.2.4).  
In particles containing only HΔ80αCD20 but no FΔ32, stronger signals for the H 
protein were observed (lane 2). The p24 protein, that is part of the HIV-1 capsid, 
could be detected in all four vector productions, demonstrating, that particles are also 
produced in the absence of any glycoproteins (lane 4). Analysis of p24 suggested an 
increased protein expression level compared to TPMV glycoproteins.  
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Figure 31: Biochemical confirmation of assembly of TPMV-pseudotyped lentiviral vectors 
Concentrated vector particles were analyzed by Western Blot using αHecto, αFecto and αp24-
antibody, respectively. As control, cell lysates of HΔ84αCD20, FΔ32 or untransfected (ut) cells were 
used. The positions of TPMV H, F0, F1, F1a and p24 are indicated on the left.  
 
 
 
6.5.5. Targeting of different CD20-positive and negative cell lines 
After characterization of the TPMV-pseudotyped vectors, their targeting potential was 
investigated. For this purpose, the cell lines 293T, HT1080, HT1080 that stable 
express CD20 (HT1080-CD20) and Tupaia baby fibroblasts (TBFs) were transduced 
immediately after production of the respective vector types with LV-TPMVαCD20, a 
TPMV-pseudotyped vector (TPMV HΔ80, FΔ32) that did not carry a scAb on the H 
protein (TPMV (w/o scAb)) and as controls, with LV-MVαCD20 and LV-VSV-G. After 
72 hours, GFP expression was analyzed by fluorescence microscopy and 
representative pictures were taken.  
Remarkably, LV-TPMVαCD20 showed no background transduction of the receptor 
negative cell lines 293T and HT1080 but as expected, TBF cells were transduced 
(Fig. 32). HT1080 cells that stable express CD20 (HT1080-CD20) were also 
transduced, demonstrating that cell entry occurs via the αCD20-scAb. The TPMV-
pseudotyped vector without a scAb only transduced the TPMV-native cell line TBF, 
indicating the lack of a receptor for TPMV on human cells. GFP expression in TBF 
cells is lower compared to GFP expression of HT1080-CD20 cells transduced by LV-
TPMVαCD20, for example.  
Some background transduction could be observed for LV-MVαCD20, suggesting that 
mutation of contact residues was incomplete or that vectors entered cells via the 
recently identified new MV receptor nectin-4 (Noyce et al., 2011) for which the H 
protein is not blinded yet. Apart from that, this vector type also entered cells primary 
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via αCD20-scAb, demonstrated by transduction of HT1080-CD20 cells. As expected, 
VSV-G-pseudotyped vectors entered all cell lines tested with high transduction 
efficiencies.  
 
 
Figure 32: GFP expression of different cell lines transduced with the indicated vector types 
293T cells, HT1080 cells, HT1080 cells stable expressing CD20 (HT1080-CD20) and Tupaia baby 
fibroblasts were transduced with LV-TPMVαCD20, LV-TPMV(w/o scAb) (TPMV FΔ32 and HΔ80 
without scAb) and LV-VSV-G. After 72 hours, GFP expression was analyzed by fluorescence 
microscopy (100x magnification). Representative pictures are shown. Scale bar: 200 µm 
 
 
 
6.6. Stability assays of TPMV-pseudotyped lentiviral vectors 
Up to now, the TPMV-pseudotyped vectors were concentrated by low-speed 
centrifugation and used for experiments immediately after production. But for some 
experiments it might be necessary to produce high amounts of vectors and to store 
them until needed. To investigate the stability of the new vectors and how to maintain 
their functionality, different production and storage conditions were tested.  
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6.6.1. Concentration of vector particles 
In a first step, different concentration methods of vector particles were investigated 
and the recovery calculated. The recovery indicates how many functional vector 
particles get lost during concentration. Since low speed centrifugation for 24 hours is 
very time-consuming, two more concentrating techniques were tested. The vectors 
were produced as described before and 15 ml cell supernatant, respectively, 
concentrated by low speed centrifugation (LS) for 24 h at 4000 g, ultra centrifugation 
(UC) for 3 hours at 28000 g over a 20 % sucrose cushion or by ultra filtration (UF) for 
2 hours at 4000 g. Pellets containing viral vectors were resuspended in 120 µl RPMI 
for concentrating by LS and UC, by ultra filtration the volume achieved was 240 µl.  
For LV-TPMVαCD20 and LV-MVαCD20, highest recovery was achieved by low 
speed centrifugation (48.5 % and 82.0 %, Table 4) although there was a loss of more 
than 50 % of infectious vector particles for TPMV-pseudotypes. Concentration by 
ultra centrifugation resulted in a recovery of only 6.6 % for LV-TPMVαCD20 and 39.2 
% for LV-MVαCD20. Regarding the concentrating technique of ultra filtration, there 
was a very low recovery observed for LV-TPMVαCD20 (5.4 %) but for LV-MVαCD20, 
the recovery was 73.5 % which was almost as high as for low speed centrifugation, 
respectively.  
 
Table 4: Titer and recovery of vectors after different concentration methods 
LV- Concentrated by 
Titer 
Supernatant 
[t.u./ml]a 
Volume before 
concentration 
[ml] 
Volume after 
concentration 
[ml] 
Titer after 
concentration 
[t.u./ml]a 
Recovery 
[%] 
TPMV-
αCD20 
Low speed 
centrifugation 6.9 x 10
3 15 0.12 4.2 x 105 48.5 
Ultra 
centrifugation 4.0 x 10
3 15 0.12 3.3 x 104 6.6 
Ultra filtration 1.1 x 104 15 0.24 3.7 x 104 5.4 
MV-
αCD20 
Low speed 
centrifugation 4.2 x 10
3 15 0.12 4.3 x 105 82.0 
Ultra 
centrifugation 5.1 x 10
3 15 0.12 2.5 x 105 39.2 
Ultra filtration 2.4 x 104 15 0.24 1.1 x 106 73.5 
a Titer in titration units/ml [t.u./ml] 
 
Taken together, of the three tested concentration methods low speed centrifugation 
seemed to be best suited for the TPMV-pseudotyped vectors, although the recovery 
was only about 50 %. Ultra centrifugation resulted probably in damage of the 
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particles since there was only low transduction efficiency after titration of the 
concentrated vectors. Thus, concentration by ultra filtration was unsuitable for LV-
TPMVαCD20. Since there was no transduction efficiency observed for the flow 
through (data not shown), the particles seemed to attach at the membrane of the 
filter or were damaged. For LV-MVαCD20, highest recovery was achieved by low 
speed centrifugation, too, but even for UC, there was a much higher recovery than 
for LV-TPMVαCD20. Concentrating by ultra filtration resulted in high transduction 
efficiencies for the MV-pseudotypes, indicating that the vectors are still functional and 
retained by the membrane filter. As described for LV-TPMVαCD20, there was also no 
transduction observed for MV-pseudotyped vectors by titration of the flow through 
(data not shown).   
 
6.6.2. Storage of vector particles 
As mentioned before, for some experiments it is necessary to produce high amounts 
of vector particles and to store them until needed. It is also important to know the 
titers of the used vector stocks for some transduction experiments. In general, it 
takes around 72 hours to observe gene expression and to determine titers after 
titration of concentrated vectors.  
In this experiment it was investigated, if the particles could be stored in the fridge at 
4°C for 72 hours until the titer of the appropriate vector stock is determined, so that 
they could be used at the same day for further experiments. Since there is the 
assumption that the functionality of the vectors decreases when they are frozen and 
thawed, storage at 4°C for 72 hours might be an alternative.   
To investigate if there is a loss of function when vectors are frozen and thawed or 
stored at 4°C for 72 hours, TPMV- and MV-pseudotyped particles were produced as 
described before and concentrated by low speed centrifugation. Afterwards, the 
pellet was resuspended in 90 µl RPMI (+ Glutamine) of which 30 µl were used 
immediately for transduction, 30 µl were frozen at -80°C for at least two hours and 30 
µl were stored in a fridge for 72 hours (4°C) and subsequent transduction.  
Freezing and thawing of LV-TPMVαCD20 resulted in a decrease of titers of 50 % 
(Fig. 33). After storage of viral particles for 72 hours at 4°C, almost no transduction 
efficiency was observed (< 5 %), suggesting that the TPMV-pseudotypes lost their 
functionality. For LV-MVαCD20, there was a decrease of relative titer of only 2 % 
after freezing and thawing of the vector stock and after storage at 4°C for 72 hours, 
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still 25 % transduction efficiency could be achieved. Compared to TPMV-
pseudotypes, LV-MVαCD20 also lost some functionality, but was not sensitive 
towards freezing and still retained functional after a three-day-storage at 4°C.                     
        
                                                       
 
Figure 33: Loss of function after freezing and storage at 4°C of TPMV-pseudotyped particles 
Concentrated vector particles were frozen at -80°C or stored at 4°C for 72 hours and afterwards used 
for transduction of Raji cells. Titers were normalized to that obtained after transduction immediately 
after concentration by low-speed cetrifugation (100%). 
 
 
Up to now all concentrated vector types were resuspended in RPMI+ Glutamine. Now 
that a titer decrease was observed for LV-TPMVαCD20 after freezing and thawing 
and after storage at 4°C for 72 h, the cell culture medium OptiMEM was used as an 
alternative to RPMI+ Glutamine to resuspend the concentrated vector particles. This 
medium is buffered with HEPES and sodium bicarbonate and supplemented with 
hypoxanthine, thymidine, sodium pyruvate, L-glutamine, trace elements and growth 
factors (Invitrogen, complete formulation is confidential). For this experiment the 
vectors were generated as described before, but after concentration by low speed 
centrifugation they were resuspended either in RPMI+ Glutamine, OptiMEMwithout additives or 
OptiMEM supplemented with 1 % bovine serum albumin (BSA), which is often used 
as a cryoprotective agent.  
As already shown before, again there was a decrease of titers for LV-TPMVαCD20 
(60 %) when the vectors were frozen and thawed and resuspended in RPMI after 
concentration (Fig. 34). Using OptiMEM without any additives resulted in a decrease 
of titers of 40 % for TPMV-pseudotypes, which was also observed for 
OptiMEM+1%BSA, suggesting that OptiMEM retained functionality of vector particles 
but BSA had no additional cryoprotective effect. For LV-MVαCD20, there was an 
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increase of titers after freezing and thawing of the vectors (18 - 35 %), independently, 
which medium was used to resuspend the vectors after concentration, assuming, that 
a freeze cycle has an enhancing effect of transduction.  
 
                                        
Figure 34: Loss of function of LV-TPMVαCD20 can partially be rescued after freezing in 
OptiMEM 
Concentrated vector particles were resuspended either in RPMI, OptiMEM or OptiMEM supplemented 
with 1 % BSA (bovine serum albumin) and frozen for at least one hour at -80°C. Afterwards, vectors 
were thawed on ice and used for transduction of Raji cells. Titers were normalized to that obtained 
after transduction immediately after concentration by low-speed centrifugation (100%). 
 
 
In conclusion, it was demonstrated that the highest recovery for TPMVαCD20- and 
MVαCD20-vector particles could be achieved by low speed centrifugation. However, 
the recovery was much less for LV-TPMVαCD20 compared to LV-MVαCD20. 
Freezing and thawing resulted in a third and storage at 4°C for three days in a nearly 
complete loss of functionality for TPMV-pseudotypes, which was not observed for 
LV-MVαCD20. Resuspending the vector pellet in OptiMEM after concentration had a 
cryoprotective effect, although there was still a loss of titers of 40 %. These data 
demonstrate that TPMV-pseudotypes are not as stable as MV-pseudotyped vectors 
based on these performed concentration techniques and storage conditions. For 
further experiments TPMV- and MV-pseudotyped vectors were concentrated by low 
speed centrifugation for 24 hours at 4°C and the vector pellet was resuspended in 
OptiMEM without additives.   
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6.7. TPMV-pseudotyped vectors selectively transduce CD20-
positive cells 
Having shown that retargeted TPMV-pseudotyped lentiviral vectors could be 
generated to high titers and identified optimal production conditions, the next step 
was to test the targeting capability of the vectors. Main objective of gene therapy is 
the precise transgene expression in selected target cells, so that other cells or 
tissues remain unaffected. One of the aims of this thesis was to show selective 
transduction of CD20-positive cells.  
 
6.7.1. Selective transduction of CD20-positive cells 
For investigation of the selectivity of the retargeted TPMV-pseudotyped vectors, the 
CD20-positive cell line Raji was mixed in a ratio of 1:1 with CD20-negative myeloid 
cells (K-562) and incubated with different pseudotyped vectors at a multiplicity of 
infection (MOI) of 0.3. Vectors were generated as described above. Seventy-two 
hours post transduction, CD20 positive cells were stained with a PECy5-coupled 
antibody against CD20 and the amount of GFP-expressing cells in this population 
was analyzed by FACS.  
At a MOI of 0.3, transduction of the mixed cell population with LV-TPMVαCD20 
resulted in 15.7% GFP/CD20 double-positive cells, while CD20 negative cells 
remained almost unaffected (Fig. 35, left column, middle panel). There was virtually 
no transduction with untargeted TPMV vectors, confirming the assumption that there 
is no TPMV receptor on human cells (Fig. 35, right column, middle panel).   
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Figure 35: Selective transduction of CD20+ cells in a mixed cell population 
CD20-positive (Raji) and negative (K-562) cells were mixed (1:1) and transduced with different vector 
types (multiplicity of infection 0.3). 72 hours after transduction, the mixed population was stained 
against CD20 and GFP expression was analyzed by FACS. Untargeted TPMV-pseudotyped vectors 
were used as a negative control (LV-TPMV). GFP: green fluorescent protein; VSV-G: vesicular 
stomatitis virus G protein 
 
 
Transduction efficiency of the LV-TPMVαCD20 was higher than that of MV-
pseudotyped vectors that were used as a positive control (9.5% GFP/CD20 double-
positive cells) (Fig. 35, left column, lowest panel). VSV-G-pseudotyped particles 
transduced both cell types, although with very low transduction efficiency (Fig. 35, 
right column, lowest panel), assuming a mistake in calculating the MOI.  
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6.8. Transduction of primary human B cells 
The previous experiments demonstrated that TPMVαCD20-pseudotyped vectors 
efficiently mediate gene transfer to different CD20-positive cells and transduce only 
target cells in a mixed cell population. The next step was to investigate whether the 
vectors are able to enter primary human B cells. These cells naturally express CD20, 
so the TPMVαCD20-pseudotyped vectors are a promising tool for gene therapy 
approaches for diseases related to this cell type, like inherited immunodeficiencies, 
cancer and autoimmune diseases (Frecha et al., 2010). 
 
6.8.1. Transduction of activated primary human B cells 
Up to date, gene transfer to primary human B cells by viral vectors was not very 
successful. Lentiviral vectors pseudotyped with the vesicular stomatitis virus G 
protein (VSV-G) do enter the cells but only with low efficiency (Serafini, Naldini, and 
Introna, 2004). Recently, it was shown that lentiviral vectors pseudotyped with the 
MV glycoproteins and targeted to CD20 are able to efficiently transduce primary B 
cells. 
To test whether the novel TPMV vectors can also transduce this cell type, primary 
human B cells were isolated by negative depletion from peripheral blood 
mononuclear cells (PBMCs) and activated with a cytokine cocktail for 48 hours. The 
cocktail consisted of 50 ng/ml IL-2, 10 ng/ml IL-4, 10 ng/ml IL-10 and 300 ng/ml 
CD40-ligand. Incubation of primary B cells with these cytokines should result in 
expression of the activation marker CD69. To investigate whether CD69 could be 
detected on the cell surface, the B cells were stained with a fluorescence-coupled 
antibody and analyzed by FACS.  
Stimulation of primary human B cells with the cytokine cocktail resulted in 58.3 % 
CD69-positive cells that is equivalent to 58.3 % activated cells (Fig. 36). This number 
is less than expected, but since there is a clear shift of the population compared to 
the isotype control it was assumed that almost all of the cells were activated and that 
the low percentage number is due to the high backdround of the isotype control. 
Control experiments with a different antibody showed an activation rate of about 90 
% (data not shown).  
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Figure 36: Activated primary human B cells express CD69 
Primary human B cells were isolated and immediately activated for 48 hours with a cytokine cocktail 
containing 50 ng/ml IL-2, 10 ng/ml IL-4, 10 ng/ml IL-10 and 300 ng/ml CD40-ligand. Expression of the 
activation marker CD69 was then analyzed by FACS. left: B cells incubated with the FITC conjugated 
IgG1,κ isotype control; right: B cells incubated with FITC-conjugated αCD69-antibody   
 
 
Next, the activated B cells were incubated at an MOI of 1 with concentrated LV-
TPMVαCD20 and LV- MVαCD20. As mentioned above LV-VSV-G transduce primary 
human B cells only with low efficiency. In this experiment, concentrated LV-VSV-G 
was used for comparison at an MOI of 1 and 100. Vectors were produced as 
described before. After 72 hours, cells were stained for the B cell markers CD19 and 
CD20, and the percentage of GFP/CD19/CD20-triple positive cells was determined 
by FACS.  
The analysis showed that most of the isolated and activated B cells were 
CD20/CD19-double positive (Fig. 37). Transduction with LV-TPMVαCD20 resulted in 
65% GFP expression of CD19+/CD20+ cells (Fig. 37, A). With LV-MVαCD20, GFP 
expression was slightly lower (55.4%, Fig. 37 C). As expected, there was only low 
transduction efficiency with the VSV-G-pseudotyped vectors (10.0 %, Fig. 37, B) 
even with a MOI of 100 the transduction efficiency increased only up to 13.2 % (Fig. 
37, D).  
In conclusion, the results showed that it is possible to transduce activated primary 
human B cells with TPMV-pseudotyped vectors even with better efficiency than with 
MV-pseudotypes, compared to LV-VSV-G, where transduction efficiency is 
considerable lower. This result was confirmed with cells from a second donor (data 
not shown).  
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Figure 37: Transduction of activated primary human B cells 
Primary human B cells (CD20+/CD19+) were isolated from human peripheral blood mononuclear cells 
and transduced after activation with a cytokine cocktail with LV-TPMVαCD20 (A), LV-VSV-G (B) or 
LV-MVαCD20 (C) a an MOI of 1. LV-VSV-G was used additionally with a MOI of 100 (D). 48 hours 
after transduction, cells were stained for the B cell markers CD20 and CD19 and GFP-expression of 
CD20/CD19 double-positive cells was analyzed by FACS. GFP: green fluorescent protein; VSV-G: 
vesicular stomatitis virus glycoprotein; MOI: multiplicity of infection 
 
 
6.8.2. Transduction of quiescent primary human B cells  
Surprisingly, it was demonstrated, that LV-MVαCD20 was able to efficiently 
transduce even quiescent primary human B cells (Funke et al., 2008a), a cell type, 
that was known to be resistant against transduction with lentiviral vectors (Serafini, 
Naldini, and Introna, 2004). As a next step, it was investigated if LV-TPMVαCD20 is 
also able to transduce quiescent primary human B cells or if this is due to the MV 
glycoproteins.  
To answer this question, primary human B cells were isolated from human PBMCs 
by negative depletion and immediately transduced by LV-TPMVαCD20, LV-
MVαCD20 (MOI 1) and LV-VSV-G (MOI 1 and MOI 100). Before transduction, the 
cells were stained against the activation marker CD69 to ensure that they were not 
activated. After 48 hours, the cells were incubated with antibodies against the B cell 
markers CD19 and CD20, following analysis of GFP expression in this population by 
FACS.  
Antibody-staining of the isolated B cells shows no expression of CD69, confirming 
that they are not activated (Fig. 38).  
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Figure 38: Quiescent primary human B cells do not express the activation marker CD69 
Primary human B cells were isolated, immediately stained with an αCD69-antibody and analyzed by 
FACS. left: B cells incubated with the FITC conjugated IgG1,κ isotype control; right: B cells incubated 
with FITC-conjugated αCD69-antibody   
 
 
Remarkably, 45.2 % of quiescent B cells were transduced by the TPMV-pseudotyped 
vector (Fig. 39, A) whereas transduction efficiency for LV-MVαCD20 was slightly less 
(Fig. 39, C, 35.5 %). This confirmed the observation already made for activated 
primary human B cells, namely that LV-TPMVαCD20 transduces this cell type more 
efficient than MV-pseudotyped vector. As expected, there was virtually no 
transduction with the VSV-vectors, even not with a MOI of 100 (< 1%, Fig. 39, B and 
D).  
 
 
Figure 39: Transduction of quiescent primary human B cells 
Primary human B cells (CD20+/CD19+) were isolated from human peripheral blood mononuclear cells 
and transduced immediately with LV-TPMVαCD20 (A), LV-VSV-G (B) or LV-MVαCD20 (C) a an MOI 
of 1. LV-VSV-G was used additionally with a MOI of 100 (D). 48 hours after transduction, cells were 
stained for the B cell markers CD20 and CD19 and GFP-expression of CD20/CD19 double-positive 
cells was analyzed by FACS. GFP: green fluorescent protein; VSV-G: vesicular stomatitis virus 
glycoprotein; MOI: multiplicity of infection 
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6.8.3. Neutralization assays with retargeted LV-pseudotypes 
Viral vectors have to evade the immune system of the host to reach their target cells. 
This is problematic for MV-derived vectors for gene therapy because almost 
everybody in the general human population has measles virus antibodies, either due 
to MV vaccination or MV infection. At the beginning of this thesis it was hypothesized 
that TPMV-pseudotyped vectors would not be neutralized by human sera since no 
antibodies against TPMV are expected in the human population.  
To confirm this hypothesis and to test whether TPMV is neutralized or whether there 
is any cross-reactivity with MV-antibodies, neutralization assays were performed with 
serum containing MV antibodies, either due to vaccination (serum 1, 2) or MV 
infection (serum 3). As control, MV antibody-negative serum was used (MV-negative 
serum). The sera were incubated for 30 minutes at 56°C to inactivate the 
complement system. LV-TPMVαCD20, LV-MVαCD20 or vectors pseudotyped with 
MV glycoproteins that do not contain a scAb (LV-MV(w/o scAb)) were pre-incubated 
with four different sera in several dilutions and added to CD20-positive Raji cells. 
After 72 hours, GFP expression of transduced cell was analyzed by FACS. The 
transduction efficiency of vectors that were incubated with medium only (RPMI) was 
set as 100 % and vectors incubated with different serum dilutions were normalized to 
this value. 
Transduction efficiency of vectors pseudotyped with MV glycoproteins without scAb 
(LV-MV(w/o scAb)) dramatically decreased when vectors incubated with MV-
antibody-containing sera (sera 1, 2, 3), demonstrating that this vector type was 
neutralized even with high serum dilutions (Fig. 40). Regarding LV-MVαCD20, this 
vector type was completely neutralized only by serum 3, although transduction 
efficiency also decreased by incubation with serum 1. Serum 2 had almost no 
neutralization effect since transduction efficiency was around 80 %, even at the 
lowest serum dilution. These data indicate that the αCD20-scAb had a shielding 
effect on neutralization of this vector and that higher MV-antibody titers were 
necessary for neutralization. Transduction efficiency of TPMV-pseudotyped vectors 
(LV-TPMVαCD20) was decreased after incubation with serum 1, 2 and 3 but did not 
drop under 35 %. No complete neutralization with any of the sera was observed. 
Remarkably, transduction efficiency of all three vector types (LV-TPMVαCD20, LV-
MVαCD20, LV-MV(w/o scAb)) was decreased in the presence of serum that does not 
contain MV antibodies (MV-negative serum). For LV-TPMVαCD20, transduction 
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efficiency after incubation with MV-negative serum was similar to that obtained after 
incubation with serum 3. This observation might be due to residual activity of the 
complement system.  
In summary, these data show that MV-pseudotypes without scAb were completely 
neutralized by serum containing MV antibodies. In contrast, neutralization of LV-
MVαCD20 was less efficient, suggesting a shielding effect of the αCD20-single chain 
antibody. For this vector type, neutralization seemed to depend on MV-antibody titer 
of the serum since only with serum 3 a complete neutralization was observed. This 
serum had probably the highest MV-antibody titer because it was derived from a 
person that was infected with MV while serum 1 and 2 were from vaccinated 
individuals. For TPMV-pseudotypes, no complete neutralization was observed. 
Although the transduction efficiency decreased, it is not as significant as for the other 
vector types and since this effect was also observed for MV-negative serum, cross-
reactivity with MV antibodies could be excluded.  
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Figure 40: Neutralization assays of pseudotyped LVs with different sera containing MV 
antibodies 
To analyze if MV-antibodies have neutralizing effect on TPMV or show any cross-reactivity, lentiviral 
vectors pseudotyped with TPMV glycoproteins were incubated with different sera in different dilutions 
and transduction efficiency was investigated. Vectors pseudotyped with retargeted MV glycoproteins 
(LV-MVαCD20) or MV glycoproteins without a scAb (LV-MV(w/o scAb)) were used as controls. Serum 
1 and 2 were derived from a MV-vaccinated person, serum 3 from a person with MV infection. Serum 
MV-negative does not contain any MV antibodies. The transduction efficiency of vectors that were 
incubated with medium only (RPMI) was set as 100 % and vectors incubated with different serum 
dilutions were normalized to this value. The relative transduction efficiency shown here in percent [%] 
is the average of two independent experiments. LV: lentiviral vector; MV: measles virus; TPMV: 
Tupaia paramyxovirus; scAb: single chain antibody  
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7. DISCUSSION 
 
Gene therapy is defined as the treatment of a disease or correction of a genetic 
disorder by introducing therapeutic genes into target cells, respectively (Escors and 
Breckpot, 2010). To treat a disease or correct a genetic dysfunction, the delivery of 
therapeutic genes has to be specific to a certain cell type and gene expression has to 
be efficient. Lentiviral vectors provide a promising tool for gene therapy, since they 
allow transduction of dividing and non-dividing cells and mediate long-term gene 
expression by integration of the transgene into the target cell’s genome (Matrai, 
Chuah, and VandenDriessche, 2010). To increase specificity of gene delivery, 
different approaches have been developed, for example the use of tissue specific 
promoters so that the gene delivered by the vector is only expressed in target cells 
(transcriptional targeting) (Waehler, Russell, and Curiel, 2007). However, this method 
also affects non-target tissues since vectors can enter cells in a non-specific way. 
Therefore, an important point is to restrict cell entry of vectors to the desired cell type, 
a process called transductional targeting. This is the most desirable approach since it 
leaves other tissues or cells completely unaffected (Waehler, Russell, and Curiel, 
2007). Although there has been great success in the development of lentiviral vector 
technology, safety and efficiency of gene transfer have to be further improved 
(Bouard, Alazard-Dany, and Cosset, 2009; Waehler, Russell, and Curiel, 2007).  
Significant progress has been made in the development of MV-based vectors, but 
they are obviously unsuitable for long-term replacement gene therapy since infected 
cells are killed and there is no integration of the transgene into the genomes of the 
infected cells. MV can be targeted to many different cell types by displaying a variety 
of specificity domains on the H protein (Cattaneo, 2010; Schneider et al., 2000). 
Recently, it has been shown that the MV glyoproteins can be used to pseudotype 
lentiviral vectors (Anliker et al., 2010; Frecha et al., 2009; Frecha et al., 2008; Funke 
et al., 2008a; Funke et al., 2009). These vectors combine the versatile MV targeting 
system with the advantages of lentiviral vectors (reviewed in (Buchholz, Mühlebach, 
and Cichutek, 2009)). But since MV antibodies are widespread in the general 
population, either due to vaccination or infection with MV, neutralization of these 
vectors might be an important problem to overcome. 
Therefore, in this thesis vectors pseudotyped with glycoproteins of an alternative 
paramyxovirus were developed, namely the glycoproteins of the Tupaia 
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paramyxovirus (TPMV). They can be retargeted in a similar way to MV glycoproteins 
and since TPMV is an animal paramyxovirus that does not infect humans, no pre-
existing neutralizing antibodies are expected (Springfeld et al., 2005; Tidona et al., 
1999). Furthermore, while the MV glycoproteins have to be modified to ablate 
receptor binding of the H protein to natural MV receptors (Nakamura et al., 2005; 
Vongpunsawad et al., 2004), this is not necessary for the TPMV H protein, resulting 
in increased safety of these vectors. Hence, in this study, retargeted lentiviral vectors 
were generated that combine the advantages of MV-pseudotyped vectors with the 
advantages of TPMV glycoproteins.  
 
7.1. Characterization of TPMV glycoproteins 
The first step in the development of TPMV-pseudotyped lentiviral vectors was the 
generation and characterization of modified TPMV F and H glycoproteins. Following 
the observation that unmodified MV glycoproteins are not incorporated into LVs, eight 
TPMV H variants and seven TPMV F variants with different truncations of their 
cytoplasmic tails were generated. Additionally, a single chain antibody (scAb) against 
CD20 was displayed on all truncated H variants. Western Blot analysis showed that 
all modified proteins are expressed at levels similar to wild type.  
The TPMV glycoproteins are related to the MV glycoproteins but have some 
uncommon properties. The cytoplasmic tail of the H protein is considerably longer 
than those of all other paramyxoviruses. Previous results showed that targeting of the 
TPMV glycoproteins with a CEA scAb in analogy to MV is possible (Springfeld et al., 
2005). In this thesis, a scAb against CD20 was displayed at the ectodomain of TPMV 
H. Analysis of surface expression of the H protein variants revealed that the scAb 
does not inhibit protein processing within the cell. To test the proteins in regard to 
their function, fusion assays were performed. All truncated TPMV HαCD20 variants 
were functional. Remarkably, a truncation of 80 or 84 amino acids (aa), leaving only 
14 or 10 aa, respectively, is well tolerated in terms of function. For truncated MV H 
protein, at least 14 aa are necessary to mediate fusion. Variants with shorter CTs lost 
their functionality (Moll, Klenk, and Maisner, 2002). Demonstrating that the αCD20-
scAb on TPMV H can also be used for targeting, strengthens the evidence that the 
TPMV targeting system is as versatile as the MV system.  
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In contrast to TPMV H, truncation of the CT of the F protein by 34 or more amino 
acids is not tolerated. As demonstrated in fusion assays, F variants with a 
cytoplasmic tail of 3 or 4 amino acids lost their function since they are not able to 
mediate the formation of syncytia. Surprisingly, truncation of 33 amino acids did not 
affect syncytia formation at all, so a difference of only one amino acid determined 
functionality. This is in contrast to the truncated MV F protein where only three amino 
acids of the CT are sufficient to mediate fusion (Moll, Klenk, and Maisner, 2002).  
Regarding the details of the TPMV F protein, the F1/F2 cleavage site is different 
compared to other paramyxovirus fusion proteins and activated by a yet unidentified 
protease (Springfeld et al., 2005). In general, the F1/F2 cleavage site of 
paramyxoviruses is preceded either by one or several arginines and lysines, 
respectively, it is mono- or oligobasic (Klenk and Garten, 1994). Oligobasic cleavage 
sites are recognized by furin-like proteases in the medial- and trans-Golgi, 
monobasic cleavage sites by trypsin-like proteases on the cell surface. Exceptions 
are Nipah (NiV) and Hendra (HeV) viruses, which have amonobasic cleavage site but 
are neither cleaved by trypsin nor furin. The F0 protein of NiV and HeV is transported 
to the cell surface and subsequently endocytosed. Afterwards, it is cleaved in the 
endosome by cathepsin L into activated F1 and F2 and transported back to the cell 
surface (Lee and Ataman, 2011). TPMV has neither a mono- nor an oligobasic 
cleavage site. 
For characterization of the TPMV F protein, a new antibody (αFecto) was generated 
against a peptide located in the proteins ectodomain. Since the antibody that was 
previously used to characterize TPMV F was directed against the cytoplasmic tail 
(αFcyt), this antibody could not be used to analyze the cytoplasmic tail-deleted 
proteins. With the new antibody αFecto, a novel fragment was detected, suggesting 
that a significant fraction of the F1 protein is further cleaved into an F1a and F1b 
fragment, similar to the MV and CDV F protein (von Messling et al., 2004). F proteins 
of Morbiliviruses are contranslationally inserted into the membrane of the 
endoplasmatic reticulum (ER), glycosylated and folded with subsequent trimer 
formation (Hernandez et al., 1996). These F protein trimers are arranged into a ring-
like structure to form the fusion pore. For MV and CDV F proteins it was 
hypothesized that partial F1a/F1b cleavage induces a conformational change of the 
trimers that leads to fusion pore formation by breaking symmetry.  
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To further characterize the newly observed TPMV F1a/F1b cleavage a number of 
experiments were performed. The data revealed that the novel F1a fragment is 
transported along the secretory pathway and secreted into the supernatant of 
transfected cells. Furthermore, significant amounts were also detected in purified 
TPMV virions. The cleavage site was mapped and surprisingly, it is located within the 
outer half of the transmembrane domain of TPMV F. These results indicate that F1a 
is no longer anchored in the cell membrane and can therefore be released into the 
supernatant. The presence of F1a in virions can probably be explained by the 
formation of mixed trimer complexes that contain membrane-anchored F1 as well as 
F1a.   
The cleavage site was mapped by insertion of a Flag-tag at different amino acid 
positions in the ectodomain expecting that F1a/F1b cleavage results in loss of protein 
detection (section 6.3.1). With an αFlag-antibody, the F0 fragment of F499 could be 
detected but not of F500, indicating that the cleavage site is located between amino 
acid position 499 and 500. Surprisingly, no F1 fragment was found for F483-F499 using 
the αFlag-antibody, but when the Flag-tag was added after aa position 533 or at the 
C-terminal end of the F protein (F553), the F1 fragment was visible. 
In the case of the MV and CDV F protein, it was not possible to completely ablate F 
protein function by mutating the F1a/F1b cleavage site. Mutation or substitution of the 
respective amino acid sequence only reduced cleavage efficiency. These data 
demonstrate that factors other than the primary amino acid sequence, for example an 
exposed structure, influence protease cleavage (von Messling et al., 2004). Similar 
results were obtained by mutating the F1a/F1b cleavage site of TPMV F (section 
6.3.2). The respective amino acids were replaced by alanine residues. Replacement 
of the amino acids of the cleavage site by alanins did not result in cleavage inhibition. 
Characterization of the cleavage protease using the inhibitors Antipain, E-64 and 
Leupeptin (section 6.4.1) revealed that both F protein cleavages (F1/F2 and 
F1a/F1b) did not occur, resulting in an inactive F protein as demonstrated in fusion 
assays. These three chemicals have in common that they are cysteine protease 
inhibitors, suggesting that a cysteine protease is involved in cleavage and 
subsequent activation of TPMV F. Antipain and leupeptin are peptidyl aldehydes and 
their inhibition is reversible. E-64 is an irreversible inhibitor and belongs to the group 
of epoxysuccinyl-based inhibitors which only inhibit cysteine proteases. All three 
substances contain a peptide segment for recognition by the enzyme which is 
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coupled to a nucleophilic group. This group can attack or substitute the cysteine 
residue of the active site of the enzyme (Otto and Schirmeister, 1997).  
Interestingly, for NiV and HeV, the endosomal/lysosomal cysteine protease cathepsin 
L has been identified as an activating protease (Craft and Dutch, 2005; Meulendyke 
et al., 2005; Pager et al., 2006; Pager and Dutch, 2005). As mentioned before, NiV 
F0 is cleaved in the endosome by L cathepsin forming F1 and F2 after clathrin-
mediated endocytosis. This is due to a tyrosine-based internalization signal in its 
cytoplasmic tail, the YSRL sequence (aa 525-528) (Diederich et al., 2005). Similar 
results were obtained for HeV (Pager et al., 2006; Pager and Dutch, 2005). The 
YSRL sequence, which is located in the CT of NiV and HeV F protein, fits in the 
YXXΦ-type endocytosis signal consensus motif, whereat Y is a tyrosine, X can be 
any amino acid (aa) and Φ is a large hydrophobic aa. Tyrosine-dependent motifs are 
often involved in protein sorting and targeting signals of transmembrane proteins 
(Bonifacino and Traub, 2003). Regarding the CT of TPMV F, two tyrosine residues 
can be found at aa positions 527 and 529. At aa position 529-532 of TPMV F the 
sequence YSLR is present which is similar to the endocytosis signal of NiV and HeV. 
But since it contains an arginine instead of a hydrophobic aa at position four, it does 
not match the YXXΦ-type endocytosis signal. Another tyr-containing motif can be 
found at aa position 527-530 (YVYS), but this also lacks the hydrophobic aa at 
position four of the YXXΦ- motif. However, there are some exceptions. The Influenza 
HA protein is known to not be endocytosed, but a cytoplasmic tail mutant carrying a 
tyrosine at aa position 453 and a serine at aa position 546 (HA-Y543/S546), resulting 
in the motif YXXS, was endocytosed efficiently (Naim and Roth, 1994). Regarding 
the CT of TPMV F, the sequence YVYS (aa 527-530) is equivalent to the YXXS motif 
of the Influenza HA-mutant. Consequentially, it might act as endocytosis signal for 
TPMV F. Furthermore, it indicates that the consensus motif is possibly variable.  
Supporting this hypothesis is the detection of high amounts of F0 fragment in addition 
to F1 in Western Blot analysis of TPMV-pseudotyped vectors (section 6.5.4). This 
indicates that only a fraction of F protein was cleaved and activated on the cell 
surface which might have consequences for the generation of TPMV-pseudotyped 
LVs. Since glycoprotein expression on the cell surface is a critical step in vector 
formation, titers might be reduced due to the high amount of uncleaved F protein. In 
contrast to this observation, there was no F0 detected in TPMV virions (section 
6.2.4). Possibly, the virus has a different mechanism of F protein processing that only 
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allows incorporation of cleaved protein, for example, assembly in specialized 
domains of the cell membrane. An alternative explanation is that the truncated 
variant FΔ32 is incorporated in LVs in contrast to the full-length F protein in virions 
assuming that an endocytosis signal sequence in the CT was removed by truncation. 
Thus, endocytosis and subsequent cleavage and activation of FΔ32 might not have 
been complete.  
The experiments performed in this section revealed only preliminary results, for a 
better understanding of the mechanism behind TPMV F cleavage and activation and 
to verify the above described hypothesis, further investigation is necessary. To find 
out whether F cleavage occurs during transport along the secretory pathway or at the 
plasma membrane, protein expression of cells treated with inhibitors of the secretory 
pathway has to be analyzed. For analysis of the endocytosis hypothesis, the 
respective tyrosine residues of the TPMV F cytoplasmic tail could be mutated and 
endocytosis of the native and mutant protein could be investigated in presence or 
absence of endocytosis inhibitors. Characterization of the protease revealed that a 
cysteine protease is likely to be involved in cleavage. The most important cysteine 
proteases in mammals are calpains which can be found in the cytoplasm and 
cathepsins that are mainly located in the lysosomes (Otto and Schirmeister, 1997), 
but it has been shown that cathepsins can also be secreted when cells are stimulated 
with proinflammatory cytokines (Reddy, Zhang, and Weiss, 1995; Sukhova et al., 
1998; Turk, Turk, and Turk, 2000). Other important members of the cysteine 
protease family are caspases which are involved in apoptosis (Amarante-Mendes 
and Green, 1999). Since it was shown that the F1a/1b cleavage site is located in the 
transmembrane domain, the responsible protease could also be an extracellular 
protease. To further restrict the cysteine protease that is responsible for TPMV F 
cleavage and activation, investigation of protein expression in the presence of 
calpain inhibitors (calpeptin, PD150606), caspase inhibitors (caspase inhibitor III) or 
cathepsin inhibitors (Cath I, Cath LIII) has to be examined.  
Identification of the cleavage protease might be important since it has been reported 
that it can act as target for viral therapy. For NiV and HeV it has been shown that 
treatment of virus-infected cells with chloroquine prevents virus spread in vitro 
(Freiberg et al., 2010). Unfortunately, this effect could not be observed in a golden 
hamster model in vivo. It has been proposed that chloroquine prevents the proteolytic 
cleavage of Henipavirus F protein by cathepsin L (Porotto et al., 2009). Although 
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TPMV does not infect humans and therefore no treatment is necessary, the virus 
might be used as a model to further investigate the characteristics of the emerging 
and highly pathogenic Henipaviruses.  
The data raise the question of the biological function of the partial F1a/F1b cleavage. 
As mentioned before, one hypothesis is that proteolytic processing enhances fusion 
pore formation (von Messling et al., 2004). Another function of this cleavage could be 
that a fragment of TPMV F acts as modulator of the host’s antiviral immune 
response. Importantly, there is an example from a paramyxovirus F protein, the 
bovine respiratory syncytial virus (BRSV). Cleavage of the fusion protein results in a 
small fragment that is converted into a biologically active molecule by additional 
posttranslational modifications (Zimmer, Rohn et al. 2003). This molecule is called 
virokinin and can interact with tachikinin receptors of the host that are involved in 
local inflammatory and immune processes.  
Although there are still open questions about the mechanism of F protein activation, 
the TPMV glycoproteins share many features with MV glycoproteins that make them 
so suitable for pseudotyping of lentiviral vectors.  
 
7.2. Pseudotyping of lentiviral vectors with TPMV glycoproteins 
After characterization of TPMV glycoprotein variants they were screened in all 
combinations for their ability to pseudotype lentiviral vectors. Screening revealed that 
the F protein variant with a 6-amino acid tail (F∆32) together with the H variant with a 
tail length of 14 aa (H∆80αCD20) resulted in the highest vector titers (section 6.5.2). 
As already mentioned for the fusion assays, truncations of the long cytoplasmic tail of 
TPMV H were surprisingly well tolerated. Although the fusogenicity of the protein was 
reduced when the cytoplasmic tail was truncated, there was no complete loss of 
function when a certain tail length was reached. In contrast to TPMV H, no functional 
vectors could be generated with TPMV F proteins with truncations of more than 33 
amino acids. Interestingly, transduction was achieved with FΔ33 but not with FΔ34 or 
FΔ35. Apparently, a difference of only one amino acid prevents functional LV-
pseudotyping. This could be due to a loss of function of these proteins or to low or 
even no incorporation levels into LVs. But as fusion assays have demonstrated that F 
proteins with short CT do not form syncytia, there is probably a loss of function of 
these F variants. Replacing the CT of TPMV F with that of truncated MV F protein 
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also did not lead to a functional protein,. An interesting observation was that even 
TPMV glycoproteins without any CT truncations were able to pseudotype LVs, 
although titers were low. This is in contrast to MV-pseudotypes. No vectors could be 
generated with full-length glycoproteins. Different results were also obtained 
regarding the length of the CT. For the MV F protein, a truncation of the cytoplasmic 
tail to three amino acids was found to result in the highest vector titers (Frecha et al., 
2008; Funke et al., 2008b). Similar results had been obtained previously with the F 
protein of Sendai virus that had a cytoplasmic tail truncation to four amino acids 
(Kobayashi et al., 2003). For the MV H protein, conflicting results have been 
published: while one group found a truncation to 16 amino acids most effective 
(Funke et al., 2008b), another group reported a truncation to 10 amino acids to be 
optimal (Frecha et al., 2008). An explanation for the differences between MV and 
TPMV could be that the cytoplasmic tails have no sequence similarities. In 
conclusion, it was not possible to directly transfer the results obtained for MV to 
TPMV but CT optimal truncations of both glycoproteins are approximately in the 
same range. For the F proteins, keeping the CT as short as possible was most 
effective to maintain function. Another difference to the MV system is that the 
attempts to increase vector titers by using different ratios of the TPMV F and H 
plasmids during vector production were not successful. For MV it was reported that a 
H:F plasmid ratio of 1:7 increased titers by up to ten-fold compared to the same 
amounts of H and F plasmids. In cells infected naturally with MV, there is a gradient 
of mRNA due to the MV gene order. Accordingly, more F than H mRNA is produced 
in MV infected cells (Cattaneo et al., 1987b; Plumet, Duprex, and Gerlier, 2005). 
Thus, the situation in natural MV infected cells is simulated by the use of higher 
amounts of F plasmid. However, an increase of the amount of TPMV F plasmid had 
no effect on vector titer although gene order in the TPMV genome is the same as for 
MV.  
Regarding stability assays performed in this thesis it is obvious that the TPMV-
pseudotypes are not as stable as MV-pseudotypes. But finally, vector titers similar to 
those in the MV system were achieved. Compared to lentiviral vectors pseudotyped 
with VSV, these titers are still low and for using them in gene therapy trials, vector 
production has to be further improved. To further increase vector titers, a more 
detailed understanding of the requirements for glycoprotein incorporation into 
lentiviral particles and of the molecular biology of TPMV will probably be necessary.   
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To investigate the specificity of the TPMV-pseudotyped vectors, different cell lines 
were transduced with different vector types (section 6.5.5). There was virtually no 
background transduction with TPMV-pseudotypes, demonstrating the absence of a 
receptor for TPMV and the CD20-mediated specific entry of the vectors. This is in 
contrast to MV-pseudotypes, where some background transduction could be 
observed. This might be due to incomplete mutation of the CD46/SLAM contact 
residues or other receptors, e.g. nectin-4 (Noyce et al., 2011). The MV glycoproteins 
used as controls in this thesis are so far blinded against this receptor. Specificity of 
TPMVαCD20-LVs was furthermore demonstrated by transduction of a mixed cell 
population of CD20-positive and –negative cells (section 6.7). TPMV-pseudotyped 
vectors selectively entered CD20-positive cells while VSV-G pseudotyped vectors do 
not discriminate between the two cell lines. 
An important point of this thesis was the transduction of primary human B 
lymphocytes. Previous reports described that lymphocytes require stimulation with 
cytokines or other factors for transduction with lentiviral vectors (Serafini, Naldini, and 
Introna, 2004; Unutmaz et al., 1999). Remarkably, transduction of stimulated human 
B cells with LV-TPMVαCD20 resulted in 65.0 % GFP-positive cells (section 6.8.1). 
Regarding LVs pseudotyped with VSV-G, they are able to transduce most target 
cells, but transduction levels of human B cells even under optimized conditions are 
low (Bovia et al., 2003; Janssens et al., 2003). In this study when using an MOI of 
100 only 13.2 % of the stimulated B cells were GFP-positive after transduction. 
Hence, the retargeted TPMVαCD20 glycoproteins are significantly more efficient in 
mediating gene transfer to primary human B cells than the VSV glycoprotein.  
Gene transfer into quiescent lymphocytes might be of even more importance for 
gene therapy approaches than in activated lymphocytes, since they are involved in 
many diseases, like inherited immunodeficiencies, cancer and autoimmune diseases 
(Frecha et al., 2010). Quiescent lymphocytes remain in the G0 phase of the cell cycle 
until they are stimulated. During this time, the cell size is reduced and transcription 
and translation rates as well as  metabolism are down regulated (Buchholz, 
Mühlebach, and Cichutek, 2009). Viral infection of cells in the G0 phase does not 
lead to the respective post-entry steps like reverse transcription of the virus genome 
and transport to the nucleus. Consequently, the transgene is not integrated in the 
host genome (Korin and Zack, 1998; Yoder et al., 2008). After stimulation, for 
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example by cytokines or receptor binding, the cell enters the G1 phase and down 
regulation is reversed.   
Recently, efficient transduction of quiescent primary human lymphocytes with 
measles virus pseudotyped LVs was reported independently by two different groups 
(Frecha et al., 2011; Zhou et al., 2011). Unexpectedly, binding to both natural 
receptors (CD46 and SLAM) of the MV vaccine strain seems to be necessary. 
However, lentiviruses pseudotyped with a mutated MV H protein were unable to 
mediate entry via CD46 or SLAM, but when targeted with a αCD20-scAb could also 
be used to transduce quiescent B cells (Funke et al., 2008b). In this thesis it was 
shown that LVs pseudotyped with TPMV glycoproteins carrying the same αCD20-
scAb also mediate efficient gene transfer into quiescent primary human B cells (45.2 
% GFP-positive cells)  Efficiency was even higher than MVαCD20-LVs that were 
used with the same MOI as control (35.5 % GFP-positive cells) (section 6.8.2). The 
quiescent lymphocytes were not transduced by VSV-G-pseudotyped LVs, even when 
a high multiplicity of infection (MOI 100) was used. 
For the targeted MV-pseudotyped vectors two mechanisms were proposed 
(Buchholz, Mühlebach, and Cichutek, 2009) that mediate transduction of quiescent 
lymphocytes. Regarding the first mechanism it has been speculated that residual 
binding of the H protein to CD46 and SLAM might induce changes in the actin 
rearrangement and microtubule formation of the target cells that make them 
susceptible for lentiviral transduction (Buchholz, Mühlebach, and Cichutek, 2009). 
Another hypothesis is that binding of the retargeted MV H protein to CD20 acts as a 
proliferative stimulus and as a consequence, resting B cells are activated and 
become susceptible for transduction. The results obtained in this thesis using 
retargeted TPMV-pseudotyped vectors exclude the first hypothesis as TPMV does 
not enter cells via the receptors CD46 and SLAM. But the retargeted TPMV H protein 
carries the same αCD20-scAb as the retargeted MV H protein, confirming that 
binding of the scAb to CD20 is sufficient to mediate transduction of quiescent primary 
human B cells. This observation supports the hypothesis that binding to CD20 
induces an activation signal, leading to susceptibility towards vector entry.  
The natural role of the CD20 molecule is still not fully understood. Although an anti-
CD20, B-cell-specific monoclonal antibody (Rituximab) has been approved for 
several years for treatment of immune diseases like Non-Hodgkin’s lymphoma and 
rheumatoid arthritis, the underlying molecular mechanism has not been completely 
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resolved. However, further investigation of the CD20 molecule and post-entry steps 
of pseudotyped lentiviral vectors are necessary to reveal the molecular mechanism of 
the CD20 molecule.  
At the beginning of this thesis it was postulated that the TPMV glycoproteins are 
similar enough to MV glycoproteins to provide all properties for efficient pseudotyping 
but different enough to escape neutralization by MV antibodies. To verify this 
hypothesis neutralization assays with TPMV-pseudotyped vectors were performed 
(section 6.8.3). Serum containing MV antibodies, either due to vaccination or 
infection, was used in these experiments. Since the TPMV glycoproteins only have 
low similarity to MV glycoproteins in their amino acid sequences (TPMV F: 33.4 %; 
TPMV H: < 20 %), no cross-reactivity was expected. Indeed, compared to the control 
vector pseudotyped with non-targeted MV glycoproteins, the TPMV-pseudotyped 
vectors escape neutralization. There is a slight decrease of the relative transduction 
efficiency for LV-TPMVαCD20 but since this effect was also observed for MV-
negative serum with increasing serum concentrations, this might be due to other 
factors than cross-reactive antibodies, for example the complement system. 
Interestingly, the retargeted MVαCD20 vectors were not neutralized as much as the 
non-targeted vectors, suggesting that the scAb displayed on the MV H protein 
provides a shielding effect. But with higher antibody concentrations the shielding 
effect is ablated. This experiment demonstrates that glycoprotein exchange of 
pseudotyped vectors with glycoproteins of an animal virus provides an escape option 
from neutralizing antibodies. A similar effect was recently described for a mutant MV 
where the MV glycoproteins were replaced by the glycoproteins of the animal 
paramyxovirus Canine distemper virus (CDV). In an animal model it was shown that 
the therapeutic effect of the envelope-exchanged virus was not affected by MV 
antibodies (Miest et al., 2011). Now it has to be investigated if TPMV-pseudotyped 
LVs are also able to escape MV neutralizing antibodies in vivo.  
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7.3. Outlook 
The results obtained in this thesis demonstrate that it is possible to generate lentiviral 
vectors with paramyxovirus envelope proteins of a non-human virus that will not be 
neutralized by preexisting antibodies in patients. This is an important advantage 
towards MV glycoproteins used for pseudotyping. The TPMV glycoproteins possess 
all properties of MV glycoproteins making them interesting for pseudotyped LVs for 
gene therapy. They can be retargeted, they are incorporated into LVs when their CTs 
are truncated and the titers obtained are similar to those obtained with MV 
glycoproteins. Additionally, TPMV proteins escape neutralization by MV antibodies. 
This is also the first time, that a LV pseudotyped with other proteins than MV proteins 
could achieve transduction of quiescent primary human B cells. 
One potential disadvantage of these newly developed vectors is their lower stability 
compared to MV-based LVs. This might be critical when it is necessary for gene 
therapy to produce large amounts of vectors that can be stored for a longer period. 
To overcome this problem, possibly further protein modifications are necessary to 
increase titers and stability. Since TPMV is an animal paramyxovirus, the TPMV 
glycoproteins probably have to be adapted to the human transcription and translation 
machinery. This can be done for example by modification of the codon usage. For 
the generation of Human Papilloma virus (HPV) virus-like particles it was shown that 
codon optimization increased protein-levels by about 100-fold (Mossadegh et al., 
2004). Converting the codons of TPMV glycoproteins to those more common in 
human genes might increase protein expression and thereby incorporation levels into 
the viral envelope. Another attempt to increase stability and titers is to exchange the 
cytoplasmic tails of the TPMV glycoproteins. It has recently been reported that LVs 
pseudotyped with rabies virus glycoproteins show increased incorporation levels 
when the rabies CT is replaced by the CT of VSV (Carpentier et al., 2011). Since 
VSV-G-pseuodtyped LVs are very stable, it might be possible to increase stability of 
TPMV-pseudotypes by exchanging the cytoplasmic tail of the F protein as it was 
done with chimeric rabies/VSV-G-pseudotyped vectors.  
For the TPMV H protein it was shown that retargeting with αCEAscAb and 
αCD20scAb is possible, suggesting that the TPMV system is as versatile as the MV 
system. Since most cell types targeted for gene therapy express unique surface 
antigens against which scAbs can be generated, the results obtained in this thesis 
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open the exciting perspective of targeted lentiviral transduction of any target tissue 
after systemic administration of gene therapy vectors.  
TPMV vectors will certainly induce neutralizing antibodies when administered 
systemically to patients. Since in many cases repeated administration of gene 
therapy vectors will probably be necessary for efficient transduction of the target 
tissue, it might be reasonable to further pursue the identification of other animal 
paramyxovirus envelope proteins that, like TPMV, can be targeted and used to 
pseudotype lentiviral vectors. 
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